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PREFACE
The Occupational Safety and Health Act of 1970 emphasizes the need 
for standards to protect the health and safety of workers exposed to an 
ever-increasing number of potential hazards at their workplace. The 
National Institute for Occupational Safety and Health has projected a 
formal system of research, with priorities determined on the basis of 
specified indices, to provide relevant data from which valid criteria for 
effective standards can be derived. Recommended standards for occupational 
exposure, which are the result of this work, are based on the health 
effects of exposure. The Secretary of Labor will weigh these 
recommendations along with other considerations such as feasibility and 
means of implementation in developing regulatory standards.
It is intended to present successive reports as research and 
epidemiologic studies are completed and as sampling and analytical methods 
are developed. Criteria and standards will be reviewed periodically to 
ensure continuing protection of the worker.
I am pleased to acknowledge the contributions to this report on 
acrylamide by members of the NIOSH staff and the valuable constructive 
comments by the Review Consultants on acrylamide, by the ad hoc committees 
of the American Conference of Governmental Industrial Hygienists, American 
Academy of Occupational Medicine, American Academy of Industrial Hygiene, 
and American Occupational Medical Association, and by Robert B. O'Connor, 
M.D., NIOSH consultant in occupational medicine. The NIOSH recommendations 
for standards are not necessarily a consensus of all the consultants and
professional societies that reviewed this criteria document on acrylamide. 
The use of trademarks in this criteria document does not imply endorsement 
by the Health, Education, and Welfare Department. A list of Review
Consultants appears on page vi.
John F. Finklea, M.D.
Director, National Institute for 
Occupational Safety and Health
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The Division of Criteria Documentation and Standards 
Development, National Institute for Occupational Safety and
Health, had primary responsibility for development of the
criteria and the recommended standard for acrylamide. The 
Division review staff for this document consisted of Keith 
H. Jacobson, Ph.D. (Chairman), Howard L. McMartin, M.D., 
Richard A. Rhoden, Ph.D., with Seymour D. Silver, Ph.D., 
Charles S. McCammon, Jr. (Division of Physical Sciences and 
Engineering) and Jack 0. Geissert (Division of 
Surveillance, Hazard Evaluations, and Field Studies).
Stanford Research Institute (SRI) developed the basic 
information for consideration by NIOSH staff and 
consultants under contract CDC-99-74-31. Craig R.
McCormack had NIOSH program responsibility and served as
criteria manager.
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I. RECOMMENDATIONS FOR AN ACRYLAMIDE STANDARD
The National Institute for Occupational Safety and Health (NIOSH) 
recommends that employee exposure to acrylamide in the workplace be 
controlled by adherence to the following sections. The standard is
designed to protect the health and safety of employees for up to a 10-hour
work shift, 40-hour workweek, over a working lifetime. Compliance with all
sections of the standard should prevent adverse effects of acrylamide on 
the health and safety of employees. Sufficient technology exists to permit 
compliance with the recommended standard. Although the workplace 
environmental limit is considered to be a safe level based on current 
information, it should be regarded as the upper boundary of exposure and 
every effort should be made to maintain the exposure at levels as low as is 
technically feasible. The criteria and standard will be subject to review 
and revision as necessary.
Synonyms for acrylamide include propenamide, acrylic amide, and 
akrylamid. The terms "acrylamide" or "acrylamide monomer" are used in this 
document interchangeably. "Action level" is defined as a time-weighted 
average (TWA) concentration of one-half the environmental limit.
"Occupational exposure to acrylamide," because of systemic effects and 
dermal irritation produced by contact of acrylamide with the skin, is 
defined as work in an area where acrylamide is stored, produced, processed, 
or otherwise used, except as an unintentional contaminant in other 
materials at a concentration of less than 1% by weight. If an employee is 
occupationally exposed to airborne concentrations of acrylamide in excess 
of the action level, then all sections of the recommended standard shall be
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complied with; if the employee is occupationally exposed at or below the 
action level, then all sections of the recommended standard shall be 
complied with except Section 8.
Section 1 - Environmental (Workplace Air)
(a) Concentration
The employer shall control workplace concentrations of acrylamide so 
that no employee is exposed at a concentration greater than 0.3 milligram 
per cubic meter of air determined as a TWA concentration for up to a 
10-hour work shift, 40-hour workweek.
(b) Sampling and Analysis
Procedures for the collection and analysis of environmental samples 
shall be as provided in Appendices I and II, or by any method shown to be 
at least equivalent in accuracy, precision, and sensitivity to the methods 
specified.
Section 2 - Medical
Medical surveillance shall be made available to all persons subject 
to occupational exposure to acrylamide as described below.
(a) Preplacement medical examinations shall include:
(1) Comprehensive medical and work histories with special 
emphasis to such areas as weight loss and neurologic disturbances.
(2) Complete physical examination giving particular 
attention to the skin, eyes, and nervous system.
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(3) Judgment of the worker's ability to use positive- or
negative-pressure respirators.
(b) Periodic examinations shall be made available on an annual 
basis, or as otherwise determined by the responsible physician. These 
examinations shall include at least:
(1) Interim medical and work histories.
(2) Weekly examination by trained personnel of the
fingertips of hands and other portions of the body exposed to acrylamide
for evidence of skin peeling.
(3) Physical examination as outlined in paragraph (a)(2) of
this section.
(c) In an emergency involving exposure to acrylamide, all affected
personnel shall be provided immediate first-aid assistance and prompt
medical attention, especially with respect to the skin and eyes. Medical 
attendants shall be informed of the need of observation and followup for 
any delayed neurologic effects.
(d) In the event of skin contact with acrylamide, grossly
contaminated clothing and shoes shall be removed. Any exposed body area 
shall be immediately and thoroughly washed with soap and water. In the 
case of eye contact with acrylamide, eyes shall be flushed with copious 
amounts of water and a physician shall be consulted promptly.
(e) Pertinent medical records shall be maintained by the employer 
for all employees occupationally exposed to acrylamide. Such records shall 
be retained for 20 years after termination of employment. These records 
shall be made available to the designated medical representatives of the
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Secretary of Labor, of the Secretary of Health, Education, and Welfare, of 
the employer, and of the employee or former employee.
Section 3 - Labeling and Posting
All labels and warning signs shall be printed both in English and in 
the predominant language of non-English-reading employees. All employees 
shall be trained orally and informed of the hazardous areas, with specific 
instructions given to illiterate employees and employees reading only 
languages other than that used on labels and posted signs.
(a) Labeling
Containers of acrylamide shall carry in a readily visible location a 
label stating:
ACRYLAMIDE
(PROPENAMIDE)
IRRITATING TO SKIN AND EYES 
REPEATED SKIN CONTACT, INHALATION, OR SWALLOWING 
MAY CAUSE NERVE DAMAGE
Avoid contact with skin, eyes, and clothing.
Avoid prolonged or repeated breathing of dust, mist, or vapor.
Wash thoroughly after handling.
Use with adequate ventilation.
Keep away from heat.
First Aid: In case of skin or eye contact, flush with plenty
of water; call a physician.
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(b) Posting
Areas where acrylamide is present shall be posted with a sign 
reading:
ACRYLAMIDE
(PROPENAMIDE)
IRRITATING TO SKIN AND EYES
REPEATED SKIN CONTACT, INHALATION, OR SWALLOWING 
MAY CAUSE NERVE DAMAGE
Avoid contact with skin, eyes, and clothing.
Avoid prolonged or repeated breathing of dust, mist, or vapor.
Do not enter areas where used, unless adequately ventilated.
Section 4 - Personal Protective Equipment
(a) Protective Clothing
(1) Appropriate protective clothing, including gloves, 
aprons, long-sleeved overalls, footwear, and face shields (8-inch minimum), 
shall be worn where needed to limit skin contact with acrylamide. 
Impervious clothing may be needed in specialized operations. Appropriate 
eye protection (chemical safety goggles or face shields and safety glasses 
with side shields) shall be worn in any operation in which acrylamide 
(solid, liquid, or spray) may come in contact with eyes.
(2) The employer shall provide the employee with the 
appropriate equipment specified in paragraph (a)(1) of this section.
(b) Respiratory Protection
(I) Engineering controls shall be used if needed to keep
acrylamide concentrations at or below the TWA environmental limit.
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Respiratory protective equipment may be used:
(A) During the time necessary to install or test the 
required engineering controls.
(B) During emergencies or during the performance of 
nonroutine maintenance or repair activities which may cause exposures at 
concentrations in excess of the TWA environmental limit.
(2) When a respirator is permitted by paragraph (b)(1) of 
this section, it shall be selected and used pursuant to the following 
requirements:
(A) The employer shall establish and enforce a
respiratory protective program meeting the requirements of 29 CFR 1910.134.
(B) The employer shall provide respirators in 
accordance with Table 1-1 and shall ensure that the employee uses the 
respirator provided when necessary. The respiratory protective devices 
provided in conformance with Table 1-1 shall comply with the standards 
jointly approved by NIOSH and the Mining Enforcement and Safety 
Administration (formerly Bureau of Mines) as specified under the provisions 
of 30 CFR 11.
(C) Respirators specified for use in higher
concentrations of acrylamide may be used in atmospheres of lower 
concentrations.
(D) The employer shall ensure that respirators are
adequately cleaned and maintained, and that employees are instructed in the 
proper use and testing for leakage of respirators assigned to them.
(E) Respirators shall be easily accessible, and
employees shall be informed of their location.
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TABLE 1-1 
RESPIRATOR SELECTION GUIDE
Concentration Respirator Type
Less than or 
equal to 1 ppm 
(3 mg/cu m)
Supplied-air respirator, demand (negative 
pressure) mode, with half-mask facepiece
Less than or 
equal to 5 ppm 
(15 mg/cu m)
(1) Supplied-air respirator, demand mode, 
with full facepiece
(2) Self-contained breathing apparatus, 
demand mode, with full facepiece
Less than or 
equal to 100 ppm 
(300 mg/cu m)
(1) Supplied-air respirator, continuous- 
flow type or pressure-demand (positive 
pressure) mode, with half-mask or full 
facepiece
(2) Supplied-air respirator, continuous- 
flow type, with hood, helmet, or suit
Greater than 
100 ppm 
(300 mg/cu m)
(1) Self-contained breathing apparatus 
with full facepiece operated in pressure- 
deipand or other positive-pressure mode
(2) Combination Type C supplied-air 
respirator with full facepiece operated in 
pressure-demand mode, with an auxiliary 
self-contained air supply
Emergency entry 
(into an area of 
unknown concen­
tration)
(1) Self-contained breathing apparatus 
with full facepiece operated in pressure- 
demand or other positive-pressure mode
(2) Combination Type C supplied-air 
respirator with full facepiece operated in 
pressure-demand mode, with an auxiliary 
self-contained air supply
Escape (from an 
area of unknown 
concentration)
(1) Gas mask, full facepiece, equipped 
with a combination organic vapor canister 
and a high-efficiency filter
(2) Self-contained breathing apparatus 
operated in either demand or pressure- 
demand mode
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(F) In case of an accident which could result in 
employee exposure to acrylamide in excess of the environmental limit, the 
employer shall provide respiratory protection as listed in Table 1-1.
Section 5 - Informing Employees of Hazards from Acrylamide
(a) The employer shall ensure that each employee occupationally
exposed to acrylamide is informed at the beginning of employment or on 
assignment to an acrylamide area of the hazards, relevant symptoms such as 
skin peeling, numbness ("pins and needles" in fingers), sleepiness, loss of 
weight, and weakness, appropriate emergency procedures, and proper 
conditions and precautions for the safe use of acrylamide. People engaged 
in maintenance and repair shall be included in these training programs. 
The employee shall be reinformed at least once a year. Each employee shall 
be advised of the availability of such relevant information kept on file, 
including the material safety data sheet.
(b) Required information shall be recorded on the "Material Safety
Data Sheet" shown in Appendix III, or on a similar form approved by the 
Occupational Safety and Health Administration, US Department of Labor.
Section 6 - Work Practices
(a) Engineering Controls
(1) Ventilation systems if used shall be designed to 
prevent the accumulation or recirculation of acrylamide in the workplace, 
to maintain acrylamide concentrations at or below the recommended 
environmental limit, and to effectively remove acrylamide from the
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breathing zones of employees. Ventilation systems shall be subject to 
regular preventive maintenance and cleaning to ensure effectiveness, which 
shall be verified by periodic performance measurements.
(2) A partially enclosed, ventilated, and automated system 
should be used to empty and transfer bags of solid acrylamide into a bin, 
so that dust are effectively removed. The bag should be cut open 
automatically and any dust should be removed by local exhaust ventilation.
(3) Concrete floors in operations areas shall be sealed in 
a manner that minimizes permeation of acrylamide into the concrete.
(b) Storage, Handling, and General Work Practices
(1) Containers of acrylamide shall be kept tightly closed
when not in use. Only properly informed, trained, and equipped personnel 
shall be involved in storing, loading and unloading, or processing 
acrylamide.
(.2) Acrylamide contact with skin and eyes of workers shall
be prevented. Equipment, walls, and floors should be kept clean to limit 
worker exposure.
(3) Prior to maintenance work, sources of acrylamide and 
its vapor shall be eliminated to the extent feasible. If concentrations at 
or below the recommended workplace environmental limit cannot be ensured, 
respiratory protective equipment as specified in Table 1-1 shall be used 
during such maintenance work.
(4) Employees whose skin becomes contaminated with
acrylamide s]iall immediately wash or shower to remove all traces of 
acrylamide from the skin. Clothing contaminated with acrylamide shall be 
disposed of or cleaned before reuse.
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(5) Any spills shall be either wet vacuumed or mopped up
immediately and either decontaminated or disposed of appropriately in 
covered drums as contaminated waste; the spill area shall be decontaminated 
by washing.
(c) Waste Disposal
Solid acrylamide waste shall be disposed of either by burial in an
environmentally acceptable manner or by burning in an approved manner. 
Liquid acrylamide waste shall be drained to a sump for subsequent 
treatment.
(d) Confined Spaces
(1) Confined spaces which previously contained acrylamide 
shall be thoroughly aerated, as well as inspected and tested for oxygen 
deficiency, acrylamide, and other known contaminant exposure concentrations 
prior to entry.
(2) Individuals entering confined spaces where they may be 
exposed to acrylamide shall wear respirators as outlined in Section 4.
(3) Confined spaces shall be ventilated while work is in 
progress to keep the concentration of acrylamide at or below the workplace 
environmental limit.
(4) When a person enters a confined space, another properly 
protected worker shall be on standby outside.
(e) Emergency Procedures
For all work areas where there is a reasonable potential for 
accidents involving acrylamide, the employer shall take all necessary steps 
to ensure that employees are instructed in and follow the procedures
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specified below and any others appropriate for a specific operation or
process.
(1) Procedures shall include prearranged plans for 
obtaining emergency medical care and for the necessary transportation of 
injured workers. Employees shall also be trained in administering 
immediate first aid and shall be prepared to render such assistance when 
necessary.
(2) Approved eye, skin, and respiratory protection as
specified in Section 4 shall be used by persons involved in the cleaning
procedure of the accident site.
(3) All persons who may be required to shut off sources of
acrylamide, clean up spills, and repair leaks shall be properly trained in 
emergency procedures and shall be adequately protected against attendant
hazards from exposure to acrylamide.
(4) Employees not essential to clean-up operations shall be 
evacuated from exposure areas during emergencies. Perimeters of hazardous 
exposure areas shall be delineated, posted, and secured.
(5) Eyewash fountains and showers shall be provided in
accordance with 29 CFR 1910.151.
Section 7 - Sanitation
(a) Food preparation, dispensing (including vending machines), and 
eating shall be prohibited in work areas where acrylamide is present.
(b) Employees who handle any form of acrylamide shall be 
instructed to wash their hands thoroughly with soap or mild detergent and 
water before eating, smoking, or using toilet facilities.
(c) All contaminated gloves shall be washed before removal.
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Section 8 - Monitoring and Recordkeeping Requirements
Within 6 months of the promulgation of a standard based on these 
recommendations, each employer who has a place of employment in which 
acrylamide is present shall determine by an industrial hygiene survey if 
exposures to airborne acrylamide at concentrations above the action level 
occur. Records of these surveys, including the basis for concluding that 
air levels are at or below the action level, shall be maintained. Surveys 
shall be repeated annually and within 30 days of any process change likely 
to result in an increase of airborne acrylamide concentrations. If it has 
been decided that the acrylamide environmental concentrations may exceed 
the action level, then the following requirements apply:
(a) Personal Monitoring
(1) A program of personal monitoring shall be instituted to 
identify and measure, or permit calculation of, the exposure of all 
employees occupationally exposed to airborne acrylamide.
(2) In all personal monitoring, samples representative of
the exposure to airborne acrylamide in the breathing zone of the employee 
shall be collected.
(3) For each TWA determination, a sufficient number of
samples shall be taken to characterize the employee exposures during each 
work shift. Variations in work and production schedules as well as 
employee locations and job functions shall be considered in deciding 
sampling times, locations, and frequencies.
(4) Each operation in each work area shall be sampled at
least once every 3 months or as otherwise indicated by a professional
industrial hygienist.
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(5) If an employee is found to be exposed to acrylamide in 
excess of the recommended TWA environmental limit, the exposure of that 
employee shall be measured at least once a week, control measures shall be 
initiated, and the employee shall be notified of the exposure and of the 
control measures being implemented. Such monitoring shall continue until 
two consecutive determinations, at least 1 week apart, indicate that the 
employee's exposure no longer exceeds the recommended environmental limit; 
routine monitoring may then be resumed.
(b) Recordkeeping
Records of environmental monitoring shall be kept by the employer for 
at least 20 years. These records shall include the dates of measurements, 
job function and location of the employees at the worksite, sampling and 
analytical methods used, number, duration, and results of the samples 
taken, TWA concentrations estimated from these samples, type of personal 
protective equipment used, and exposed employees' names. All employees 
shall have access to information on their own environmental exposures. 
Environmental records shall be made available to designated representatives 
of the Secretary of Labor, and of the Secretary of Health, Education, and 
Welfare. Pertinent medical records shall be retained by the employer for 
20 years after termination of employment. Records of environmental 
exposures applicable to an employee should be included in that employee's 
medical records. These medical records shall be made available to the 
designated medical representatives of the Secretary of Labor, of the 
Secretary of Health, Education, and Welfare, of the employer, and of the 
employee or former employee.
13
II. INTRODUCTION
This report presents the criteria and the recommended standard that 
were prepared to meet the need for preventing occupational disease or 
injury arising from exposure to acrylamide. The criteria document fulfills 
the responsibility of the Secretary of Health, Education, and Welfare under 
Section 20(a)(3) of the Occupational Safety and Health Act of 1970 to 
"...develop criteria dealing with toxic materials and harmful physical 
agents and substances which will describe...exposure levels at which no 
employee will suffer impaired health or functional capacities or diminished 
life expectancy as a result of his work experience."
The National Institute for Occupational Safety and Health (NIOSH), 
after a review of data and consultation with others, formalized a system 
for the development of criteria from which standards can be established to 
protect the health and to provide for the safety of employees from exposure 
to hazardous chemical and physical agents. Criteria for any recommended 
standard should enable management and labor to develop better engineering 
controls resulting in more healthful work practices and should not be used 
as a final goal.
Development of these criteria for a recommended standard for 
acrylamide is part of a continuing series of documents published by NIOSH. 
The proposed standard applies only to workplace exposure to acrylamide 
arising from the processing, manufacture, or use of the substance as 
applicable under the Occupational Safety and Health Act of 1970. The 
standard was not designed for the population-at-large, and any 
extrapolation beyond occupational environments is not warranted. It is
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intended to (1) protect against development of systemic toxic effects and 
local effects on the skin and eyes and (2) be attainable with existing 
technology.
The major concern in occupational exposure to acrylamide is its 
potential for causing neurologic disorders. In addition, acrylamide can 
cause eye irritation and dermatitis in humans.
There are a number of areas that need further research with respect 
to acrylamide. Epidemiologic studies, carcinogenic, mutagenic, 
teratogenic, or other reproductive effects of acrylamide have not been 
found in the literature. Further, present toxicologic information on 
acrylamide is deficient in all physiologic systems other than the nervous 
system. Animal toxicity experiments of acrylamide on other organ systems 
such as the cardiovascular, pulmonary, hepatic, and renal systems have not 
been investigated. Pharmacokinetic (absorption, distribution, metabolism, 
and excretion) studies are also needed to understand the mechanism of 
action of acrylamide. Research in all these areas should be initiated. 
Improved sampling and analytical methods should also be developed.
Adherence to all provisions of the recommended standard is required 
in work areas in which acrylamide is used, regardless of the airborne 
acrylamide concentration, because the available evidence indicates that the 
greatest danger to employees exposed to acrylamide is from skin contact; 
however, inhalation hazards cannot be neglected.
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III. BIOLOGIC EFFECTS OF EXPOSURE
Extent of Exposure
Acrylamide (CH2=CHCONH2), formula weight 71.08, is a white, 
crystalline solid which is assuming increasing industrial importance as a 
chemical intermediate and as a vinyl monomer that readily undergoes 
polymerization and copolymerization [1]. Acrylamide is highly soluble in 
water and is also moderately soluble in several other common solvents such 
as methanol, ethanol, and acetone. It is thermally stable, has a vapor 
pressure of 0.007 mmHg at 25 C, and sublimes at room temperature [1]. Some 
of the more important physical and chemical properties of acrylamide are 
shown in Table XII-1 [1]. Synonyms for acrylamide include propenamide, 
acrylic amide, and akrylamid [2]. Mixtures of acrylamide with small
proportions of N,NT-methylenebisacrylamide have been marketed by American 
Cyanamid Company under the trademark AM-9 [3].
The acrylamide molecule consists of an amide and a vinyl group. It 
can undergo reactions both at the amide group and at the double bond (vinyl 
group) [1]. The double bond of the vinyl group can add halogens. The
addition of bromine was the basis of a popular method of acrylamide
analysis before gas-chromatographic and polarographic methods were used. 
Hydrolysis at the amide group with either acids or bases converts 
acrylamide to acrylic acid. Acrylamide molecules undergo 
homopolymerization and copolymerization by combining with anions in
photochemical reactions; by exposure to ionizing radiation; and, lastly, in 
the most popular and commercially useful method, by the use of free radical
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initiators of redox catalytic systems [1,4]. Molten acrylamide polymerizes 
vigorously with i_he evolution of heat [5] .
Acrylonitrile is the major starting material used in all industrial 
methods for the manufacture of acrylamide [1]. The starting material is 
mixed with sulfuric acid, an exothermic reaction, and then diluted with 
water. Acrylamide is then prepared from acrylamide sulfate either by the 
lime process, ammonia process, carbonate process, or ion-exchange process. 
Acrylamide is difficult to recover at the aqueous stage since it may 
polymerize or undergo hydrolysis. Various processes have been devised by 
manufacturers to facilitate the recovery and to control the amount of heat 
generated in the procedure. Recently, a few manufacturers have developed 
pollution- and byproduct-free processes for direct production of acrylamide 
monomer via hydration of acrylonitrile over a catalyst [6].
Acrylamide monomer production has been estimated to have amounted to 
about 15-20 million pounds in 1966, 30 million in 1969, 32 million in 1972, 
40 million in 1973, and approximately 70 million in 1974 [6]. During the 
past 20 years, the use of acrylamide polymers has also increased very 
rapidly with the increased production of acrylamide monomer [4]. In 1972, 
about 35 million pounds of acrylamide polymers were used in the United 
States alone. These are the latest years for which data are available.
The major use of acrylamide monomer is in the production of polymers 
[1]. Aqueous solutions of the monomers and a redox catalyst are used for 
soil stabilization. Polyacrylamides are very effective flocculants for 
finely divided solids in aqueous suspensions. AM-9 has found increasing 
application as a chemical grout. The largest market for acrylamide now is 
in the manufacture of polyacrylamides for waste and water treatment
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flocculants, in products for aiding sewage dewatering, and in a variety of 
products for the water treatment industry. These uses consumed more than 
40% of the acrylamide used in 1973 [6]. Acrylamide is also used to prepare 
polyacrylamides, which are used as strengtheners in papermaking and 
retention aids (to keep the fibers from being washed away). The pulp and 
paper industry accounted for about 20% of the acrylamide consumption in 
1973. Some other uses of polyacrylamides are drilling-mud additives, 
textile treatment, and surface coatings. In very small quantities, 
acrylamide polymers are also used for flocculation of ores [4,7,8], mine 
tailings and coal, friction reduction [4], thickening [4,9], soil 
stabilization, gel chromatography and electrophoresis, photography, fog 
dissipation, breaking of oil-in-water emulsions, dyeing, ceramics, and 
clarification and treatment of potable water and foods [4].
Several other uses for monomeric acrylamide have been proposed by 
various investigators. Compounds such as N,N'-ethylene-bis-acrylamide and 
some bromo combinations have shown promise as antitumor agents in mice 
[10], in tomato plant tumors [11], and in plant tissue cultures [12].
NIOSH estimates that approximately 20,000 workers are potentially 
exposed to acrylamide in the United States. Table XII-2 [3] is a list of 
occupations with potential exposure to acrylamide monomer.
Historical Reports
Monomeric acrylamide was first made in Germany in 1893 and patented 
in the United States (Patent No. 2,021,763) by the Rohm and Haas Company in 
1935. Interest was not shown in its preparation and properties until 
acrylonitrile became commercially available in 1940 [1]. It was first
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offered by American Cyanamid Company for developmental consideration in 
1952, and they began manufacture for the commercial market in 1954.
It was not until the advent of large-scale commercial production that 
some pharmacologic and toxicologic experiments were initiated by American 
Cyanamid Company at Hazleton Laboratories. After single large oral doses, 
death occurred as a consequence of convulsions and asphyxia in mice, rats, 
rabbits, and dogs. However, after repeated administration of acrylamide, a 
neurologic syndrome was characterized by postural and motor incoordination 
in these animals. The single-dose toxicity of monomeric acrylamide in 
animals was also reported by Druckrey et al [13] in 1953. The so-called 
average lethal dose by intraperitoneal (ip) injection was reported to be 
120 mg/kg in rats which died within 1 or 2 days with severe pulmonary 
obstruction. A toxicologic study reported by Hamblin [14] in 1956 showed 
that the oral administration of acrylamide monomer produced neuropathy in 
mice, rats, and dogs.
Effects on Humans
In 1953, a new method of acrylamide production was undertaken at an 
American Cyanamid Company manufacturing plant [15] where acrylonitrile was 
hydrated by sulfuric acid to form acrylamide sulfate after which it was 
neutralized by ammonia, yielding free acrylamide. About 5 months after the 
new process was begun, a "handful" of the hundreds of potentially exposed 
plant workers noticed numbness and tingling of their hands and weakness of 
their hands and legs. Dermal contact of the workers was thought to have 
been limited because they wore protective clothing and gloves. The air in 
the plant was sampled and only traces of acrylamide were found. However,
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by the use of methods (not described) of detection then in use, it was 
calculated that the maximum amount of acrylamide which could have been 
inhaled by one worker in a 5-month period was approximately 1.8 mg/kg. The 
whole manufacturing process was altered and the exposure of the workers to 
acrylamide was reduced or eliminated. Further details were not presented.
A total of 45 cases of intoxication from acrylamide have been
reported in humans [16-22, DR Brinkley, written communication, June 1976]
and up to 10 more have been suggested [15,16,19,20,23]. Of the 45, 3 were 
women (ages 17, 40, and 65), 2 children (a boy of 10 and a girl of 13), and 
40 men (18-59 years old). All of the exposures were occupationally
related, excepting a Japanese family of five who ingested and briefly used
contaminated well water for* bathing [22]. Monomeric acrylamide is a 
neurotoxin with an affinity for the peripheral ends of the spinal nerves in 
the extremities. Both motor and sensory nerves are affected but the
sensory component usually more than the motor component. In some instances
there was evidence of CNS involvement [20-22].
A pattern of reactions emerged when signs, symptoms, and results of 
neurologic examinations of the workers were compiled and compared (see 
Table III-l). Early reported symptoms typical of acrylamide intoxication 
in humans include, numbness of lower limbs [16,18,20-23], tingling of the 
fingers [18-22], tenderness to the touch [16,18], coldness [16,18],
excessive sweating of feet and hands [16-21], bluish-red skin [16,20,21],
peeling of the skin of the hands and less often of the feet [16-21], 
followed shortly by muscle weakness of the hands and feet (occasionally 
progressing to the inability to write or lift the feet when walking or 
climbing stairs) [16-23]. Later symptoms were loss of weight [17-20,23],
lassitude [16,18,21], sleepiness [20,22], and complete collapse (which 
occurred in two people after drinking alcoholic beverages) [20]. Still 
later, emotional changes [19,21-23] and finally, reactions typical of overt 
peripheral neuropathy, positive Romberg's sign [17,19-21,23,24], loss of 
vibration and position senses [17,19-21,23], weak or absent tendon reflexes 
such as the knee jerk [16-18,20-23], ataxic gait [16,20-23], foot drop 
[17,20,23], muscular atrophy (usually in the hand or thumb), and 
occasionally urinary and fecal retention [20,22] were observed. When 
patients were rested, it was found that conduction velocity was decreased 
in motor or sensory nerves or in both [21-23,25].
In hospitalized workers, clinical laboratory tests of blood, urine, 
cerebrospinal fluid (CSF), liver and kidney function, and 
electroencephalography were done [16,20,23]. Examination of the 
cardiovascular system, bones, and joints showed no pertinent deviations 
from normal [16,20,23]. These workers were only given symptomatic and 
supportive therapy. The length of time required for recovery, which was a 
few days to 2 years, was proportional to the severity of the reactions [16- 
21,23]. Only one affected worker [16] was reported to have returned to his 
occupation without further illness.
Some of the incidents of acrylamide intoxication which occurred in 
Japan were reported by Fujita et al [23] . They described in considerable 
detail the signs and symptoms which resulted from acrylamide exposure in 10 
workers in one factory. Nine men and one woman ranging in age from 17 to 
43 years were exposed at a pilot plant where manufacturing procedures were 
being developed. The length of employment in that plant varied from 3 to 
12 months before signs and symptoms appeared. All of the workers had most
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of the typical signs and symptoms of acrylamide intoxication relating more 
to the legs than to the arms. Of the three workers who were hospitalized 
because they were the most severly affected, one had been employed for 12 
months and the other two for 3 months in their present jobs. Those three 
workers had, in addition to the typical reactions (tremor and numbness of 
the hands and feet, dizziness, loss of the knee jerk, heavy feeling of the 
legs, staggering, and positive Romberg's sign), emotional changes which 
were also somewhat similar to, but very much less severe than those of the 
family reported by Igisu et al [22], which is described in detail later. 
The symptoms were attributed to the presence of the peripheral neuropathy 
and the desquamation and sensitivity of the soles of the feet, which may 
also have been in contact with acrylamide. Fujita et al [23] also found 
sufficient signs and symptoms to postulate that the CNS and probably the 
cerebellum, in addition to peripheral nerves, were involved in acrylamide 
intoxication. All 10 workers improved during about 4 months of rest and 
supportive treatment.
Takahashi et al [21] described the reactions of 13 factory and 2 
laboratory workers who were exposed to acrylamide from 2 months to 8 years. 
All of the workers were males aged 18-32 years. They were exposed during 
the polymerization of the monomer in the manufacture of papercoating 
materials. The described reactions conformed to the typical ones (numbness 
of lower limbs, ataxia, dizziness, gastrointestinal upset, and hand 
peeling). The authors [21] concluded that, although peripheral neuropathy 
was one of the most important effects in the patients, a few CNS effects 
also may have been present. When the work environment was changed to limit 
or prevent contact with acrylamide, the workers gradually recovered;
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however, the authors [21] did not describe the controls used. Takahashi et 
al [21] also performed special studies in which motor and sensory nerve 
conduction velocities and action potentials were determined in some of the 
peripheral nerves in arms and legs of the affected workers. The motor 
nerves tested had essentially normal reactions, whereas the sensory nerves' 
had decreased action potential amplitude. The authors [21] suggested that
the defect in the action potential would precede decreases in conduction
velocity and that this indicated sensory nerve injury.
Garland and Patterson [20] described six cases of acrylamide
intoxication in workers in three factories in Great Britain where 
acrylamide flocculants were produced. The workers, all men and aged 19-59 
years, had worked in the factories for periods varying from 1 to over 12 
months. Although limited details of the medical histories and examinations 
were reported, the authors [20] suggested that what was recorded agreed 
with some of the signs and symptoms of the typical reactions (increased 
sweating of feet and hands, fatigue, muscle weakness and pain, hand 
peeling, sensory loss, and positive Romberg's sign). The authors stated 
that all of the men recovered after they were removed from exposure,
although it took from 2 to 12 months. Garland and Patterson [20] 
interpreted that, because of the sleepiness of the men, the midbrain, as 
well as peripheral nerves, was involved. Fullerton [25] studied nerve 
conduction velocities in three of the patients reported by Garland and 
Patterson [20] while they were recovering from the ill effects of exposure. 
Maximal motor nerve conduction in the distal ends of median and ulnar 
nerves was found to be normal or slightly reduced and response to nerve 
stimulation in small muscles was dispersed irregularly. Fullerton
suggested that those changes were caused by degeneration and regeneration 
of the distal nerves (nerve endings near muscles). The action potentials 
of the sensory nerves were also decreased or absent; the author [25] 
indicated that the peripheral sensory nerves had been more severely damaged 
than their associated motor nerves. In addition to the determination of 
the neurophysiologic phenomena, Fullerton [25] microscopically examined 
biopsy specimens of nerves from the calf muscles from two of the three 
patients. The author [25] concluded that simultaneous nerve degeneration 
and regeneration occurred immediately after, and probably during acrylamide 
exposure, and that most probably nerve function was impaired before 
structural changes were evident.
Auld and Bedwell [16] in 1967 described in detail a mine worker's 
reaction to acrylamide exposure. The worker, a 21-year-old man, introduced 
a 10% aqueous solution of acrylamide monomer and the catalysts, 
2-dimethylaminoproprionitrile (DMAPN) and ammonium persulfate, into holes 
previously drilled into the walls of a mine. He also loaded hoppers with 
the acrylamide solution. He did not avoid contact with the chemicals, 
which often splashed onto his hands and face. After about 2 weeks on the 
job, he noticed a red rash on his forearms. About 5 weeks after the rash 
began, he complained of leg weakness and soon after, of hand weakness. He 
also stumbled when walking and had difficulty climbing stairs, writing, and 
handling eating utensils. In about 2 more weeks, he noticed blueness and 
both a sensation of cold and profuse sweating of his arms, hands and 
fingers, as well as his lower legs, feet, and toes. He reported that his 
hands and feet felt "numb and tender when touched." With increasing 
weakness, stumbling gait, and excessive sweating, he was hospitalized 14
weeks after his first exposure to acrylamide. A general physical and
neurologic examination corroborated his complaints, and the physician 
found, in addition, impairment of temperature, position and vibration 
senses, and absence of tendon reflexes (knee jerk, etc). His forearm and 
lower leg muscles were weak, and he was unsteady when standing or walking. 
Laboratory (clinical chemistry, hematology, urinalysis, and CSF) tests were 
performed, the results of which were within normal limits, except for 
elevated CSF protein which had decreased substantially at a second
determination 2 weeks later. Therefore, the authors judged it was not 
significant. Removal from exposure, supportive therapy, and rest resulted
in gradual and partial recovery in 6 weeks and in functionally complete
recovery 14 weeks after hospitalization. The authors [16] stated that, 
because of a predisposition to the effects of acrylamide as described by 
Stokinger [26], the patient was strongly advised to avoid further contact 
with acrylamide. A coworker who had been simultaneously exposed to 
acrylamide had mild symptoms which disappeared spontaneously.
Two other incidents of acrylamide exposure similar to the case 
reported by Auld and Bedwell [16] occurred in France and were described by 
Graveleau et al [17] and Cavigneaux and Cabasson [18]. Exposure occurred 
while two workers were introducing monomeric acrylamide and catalyst into 
underground drilling operations. Signs and symptoms and results of 
neurologic examinations in both workers were typical of the described 
responses (numbness of the hands and feet, excessive sweating of the limbs, 
desquamation of the hands, and positive Romberg's sign). Morviller [19] 
described four cases of acrylamide exposure and implied that there were two 
more workers who were exposed to acrylamide and acrylonitrile during a
manufacturing project in a pilot plant. Adverse effects were similar to 
the typical effects (excessive sweating, desquamation of. the hands, 
fatigue, weight loss, confusion, loss of reflexes, and pos it..: ■>.'. Horaberg' s 
sign) of acrylamide. intoxication. The author [19] also stated that the 
effects of acrylonitrile exposure were typical o£ tho^e produced by 
ae.rylamide and that exposure for an undefined length of time to 
acrylonitrile had not resulted in similar advers*..- i.t! ¡ct iuiis i.u workers.
Igisu et al [22] reported five members of a Japanese fardly who were 
exposed to acrylamide through ingestion and external «se of well water 
evidently contaminated by seepage from n system I ; operation.
They began to show symptoms about 4 weeks aft.rr t'vj groutj;.g w.vj done. Ten 
days after the onset of the symptoms, the well water was tested and found 
to contain 400 ppm of acrylamide and a trace, of DMAPW. 7i e her, father, 
and grandmother were hospitalized, with strikingly similar sv^ptoms 4-5 
weeks after the well was grouted. They ¿.■qicriencfid marked rhinorrhea, 
coughing, dizziness, and irrational behavior. Mental changes consisting of 
poor orientation and memory, confusion, and severe hallucinations preceding 
unsteadiness in walking, sleepiness, and slurred speech occurred. General 
physical and neurologic examinations showed normal or hyperactive reflexes, 
normal cranial nerve reactions, ataxic gait, (severe in both women), urinary 
and fecal retention (mother only), and ecchymoses of the extremities of 
both women. Electroencephalography showed excessive sleepiness patterns, 
but all other clinical laboratory tests performed were in the normal range. 
The only complaints referable to the skin, such as loss of touch, pain and 
sense of vibration, and a feeling of numbness in the extremities were, made 
2, 3, and 4 weeks after hospitalization by the mother, father, and
grandmother, respectively. They had mild dysesthesias of the fingers and 
feet. During the hospitalization period, the mother had no deep-tendon 
reflex response, and all three patients had slowed sensory but normal motor 
nerve conduction velocities. The two children of the family, who were away 
at school all day and presumably did not consume as much well water as the 
adults, had very mild sleep and gait disturbances (the boy) and mild 
personality changes (the girl). Both children recovered within 2 weeks. 
The father and grandmother recovered completely in 2 months and the mother 
in 4 months after hospitalization.
The Vistron Corporation (DR Brinkley, written communication, June 
1976) supplied NIOSH with information concerning airborne acrylamide 
concentrations and occupational exposures. Eight-hour acrylamide samples 
were collected daily from stationary sites in the plant using an aqueous 
impinger technique and subsequently analyzed by a colorimetric procedure 
using a ferric chloride reagent. Limited personal monitoring was 
conducted. The stationary air monitoring site data were presented as 
weekly averages and ranged from 0.1 to 0.4 mg/cu m for the control room, 
0.1 to 0.9 mg/cu m for the bagging room, and 0.1 to 0.4 mg/cu m for the 
second-floor processing area. Personal monitoring data showed that daily 
8-hour average employee exposures ranged from a low of 0.1 to as high as 
2.3 mg/cu m when stationary sites data taken on the same day showed 
concentrations ranging from 0.1 to only 0.3 mg/cu m.
Brinkley (written communication, June 1976) stated that attempts were 
made to maintain minimum employee contact with acrylamide by the 
installation of engineering controls and additional ventilation equipment 
with air-circulating fans. Emphasis was placed on personal hygiene as an
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important factor in the prevention of acrylamide intoxication. Personal 
protective equipment, such as cartridge type respirators and dust masks and 
protective clothing, such as coveralls, safety glasses, caps, and gloves, 
were also provided. Despite these precautions, two employees experienced 
neurologic symptoms in May 1974. Prior to this date, no neurologic 
symptoms except finger tingling were noted in any employee. The initial 
symptoms of erythema and skin peeling were noted in almost every employee 
who was working in the acrylamide plant. If erythema or skin peeling or 
any of the following acrylamide-associated symptoms, such as increased 
sweating of feet and hands, muscular weakness or pain, abnormal skin 
sensations, sensory loss, absent reflexes, positive Romberg's sign, 
persisted after removal of the worker from the working environment, the 
employee would be transferred outside of the acrylamide unit. According to 
Brinkley, a statistical analysis of the stationary site data and the skin 
check records has suggested that the incidence of skin reactions could, at 
least to some degree, be explained by airborne concentrations of 
acrylamide. Because of the limited personal monitoring data, airborne 
acrylamide concentrations to which workers were actually exposed could not 
be correlated with skin reactions.
Epidemiologic Studies
No reports concerning epidemiologic studies of acrylamide monomer 
were found in the published literature.
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Animal. Toxic it j_
(a) Oral Studies
Hamblin [14] reported that the single-dose oral LD50 for male albino 
mice given acrylamide as a 2 or 5% aqueous solution was 170 (130-220, 95%
confidence limits) mg/kg. Toxic signs consisted of slight tremors, 
convulsions, labored respiration, and ataxia. The single-dose oral LD50 
determined by Fullerton and Barnes [271 in 8-week.-old female albino rats 
was 203 (166-249) mg/kg. The duration of the observation period was not 
specified in either of these, studies. In a study by Keeler et: al [28], the 
single-dose oral LD50 for acrylamide was 240 (184-316) mg/kg in female rats 
and 277 mg/kg in male rats (95% confidence limits not calculable). No 
information on rat strain, age, weight, or observation period was provided.
In a 1956 study reported by Hamblin [14], repeated oral 
administration of acrylamide, 50 or 100 mg/kg/day, by stomach tube to 
albino rats produced prostration and death. The 100-mg/kg/day level killed 
all six animals after three daily doses. The 50-mg/kg/day dose caused loss 
of weight, depression, and marked weakness of the extremities; death 
occurred within 5 days after the last (15th) daily dose. Barnes [29] 
obtained qualitatively similar results in adult Porton-strain albino rats. 
Fullerton and Barnes [27] also observed that acrylamide administered to 
rats at a single dose of 100 mg/kg by stomach tube produced only fine 
tremors, but when repeated in 24 hours killed most of the animals within 3 
days. General weakness was also observed in the dying rats. When 
intubated with 50-mg/kg doses, 12 times over a 15-day period, all rats 
(number not specified) developed severe weakness and died within a few days 
after the final dose. At necropsy, many rats (both males and females) had
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gross distention of the bladder. Ten-week-old rats given acrylamide orally 
at a dose of 25 mg/kg/day, 5 days/week, developed the first signs of 
weakness after the fourth week. A dose of 10 mg/kg/day, 5 days/week, given 
for about 5 months, produced no signs of toxicity in six female rats.
Fullerton and Barnes [27] also measured motor nerve conduction 
velocity in the fibers supplying the small muscles on the plantar surface 
of the hind paws in Porton-strain albino rats. Nerve conduction velocity 
in control animals was 56 (SD 5.8) meters/second compared with 44 (SD 2.2) 
meters/second in the 11 of the 15 rats fed acrylamide in their diets (200 
ppm for 6 months or 400 ppm for 2-3 months) and showed severe neurologic 
abnormalities of the hindlimbs. The conduction velocities were normal in 
the remaining four rats recovering from the severe leg weakness.
The influence of age on acrylamide-induced leg weakness was 
investigated by Fullerton and Barnes [27] in groups of six rats (sex not 
specified) aged 5, 8, 26, and 52 weeks and fed 100 mg/kg of acrylamide at 
weekly intervals. After four doses, the youngest animals were only mildly 
affected, whereas those aged 26 weeks at the start of study were severely 
affected. The 52-week-old rats were severely affected after only three 
doses. The authors stated that, when acrylamide feeding was discontinued, 
the recovery in young animals, which had shown weakness for only a few 
weeks, was rapid and complete. For the older rats, in which weakness had 
been present for months, recovery was slow, and mild ataxia continued for 
some months.
The effects of orally administered acrylamide on dogs were briefly 
reported by Hamblin [14] in 1956, but recently have been studied in more 
detail by Thomann et al [30]. In the earlier investigation [14], groups of
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two dogs each were given acrylamide at doses of 1 mg/kg/day for 19 weeks, 
5 mg/kg/day for 5 weeks, or 8 mg/kg/day for 4 weeks without overt signs of 
toxicity. However, a dose of 10 mg/kg/day for 4-5 weeks produced 
incoordination, weakness of the extremities, and impaired righting reflex. 
A single dose of 100 mg/kg produced these same effects in 24 hours. In the 
1974 report by Thomann et al [30], experiments were performed on 6- to 
12-month-old beagles. The dogs were given acrylamide orally in gelatin 
capsules in daily doses of 5 or 15 mg/kg. The first group (three males and 
three females) received 5 mg/kg/day for 60 days; the second group (five 
males and five females) received 15 mg/kg/day for 22 days. After the first 
3 weeks of the experiment, the dogs in the 5-mg/kg/day group were inactive 
and had muscular weakness, which was particularly noticeable in the jaw 
muscles. In addition to muscular weakness, the animals in the 15-mg/kg/day 
group had dilated pupils, conjunctivitis, salivation, difficulty in 
breathing, muscular stiffness of the hindlegs, muscle twitching, head 
shaking, and convulsions. One female beagle in the latter group (15 mg/kg) 
died on day 24, 2 days after the end of treatment. Microscopic examination 
of peripheral nerves from one of the surviving dogs showed swelling of the 
myelin sheaths and fragmentation of the axons. In general, the distal 
branches of the sciatic nerve were more severely involved than were the 
proximal parts. Occasional swelling and fragmentation of nerve fibers of 
the distal branches were found in three of the six dogs in the 5-mg/kg 
group after 60 days of treatment. The authors [30] reported no structural 
alterations in the white or gray matter of the lumbar spinal cord on 
microscopic examination.
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Hopkins [31] studied the effects of acrylamide administered to five 
female and two male baboons (Papio hamadryas). The female baboons weighed 
between 12.1 and 15.4 kg and the two males weighed 9.4 and 10.3 kg. 
Acrylamide was administered in oranges or bananas as a 10% aqueous 
solution. Because the dosage schedule for one of the seven baboons was 
questionable, the data for this animal are excluded from the discussion
that follows. According to Hopkins [31] , this particular baboon was
reluctant to eat all of the fruit into which the acrylamide had been 
injected. Of the remaining six baboons, one was treated with 20 mg/kg/day 
for 29 days, another with 15 mg/kg/day for 94 days, and four with 10 
mg/kg/day for an average of 110 (89-137) days. The cumulative doses
received by the baboons were thus 580, 1,410, and about 1,100 mg/kg,
respectively. Incoordination and weakness of the hindquarters were first 
noticed on the 16th day in the 20-mg/kg/day animal, on the 42d day in the
15-mg/kg/day animal, and on an average of the 62d (42-82) day in the
10-mg/kg/day animals. Forelimb weakness first occurred on the 28th, 73d,
and 82d (61-96) days, respectively. Recovery began within 2-12 days after 
feeding was discontinued. The baboon which received a total of 580 mg/kg 
recovered completely in 62 days; those which received an average of 1,100 
mg/kg recovered in 110 days, and the baboon which received a total of 1,410 
mg/kg recovered in 270 days. The author [31] concluded that the onset of 
limbs weakness and the progression of recovery were dose dependent.
The peripheral nerves from a baboon given acrylamide at 10 mg/kg/day 
for 118 days and biopsied 19 days after the last treatment were examined by 
light microscopy [31]. The main pathologic changes were of the Wallerian 
degenerative type (degeneration of a nerve fiber which has been severed
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from its nutritive centers). Microscopic examination of transverse 
sections of nerves indicated that both motor and sensory nerves were 
affected and that there was a marked reduction in the number of myelinated 
fibers in the nerves. The author [31] reported that inspection of 
moderately affected nerves suggested the involvement of large-diameter 
myelinated fibers. The proportion of such myelinated fibers decreased with 
an increase in the duration of exposure. At necropsy, it was observed that 
long nerves to muscles were more severely affected than short nerves. 
Nerve fibers to the extremities were affected only in their distal parts, 
the proximal sciatic nerve and spinal roots remaining normal in baboons 
which showed a severe loss of myelinated fibers in nerves to muscles of the 
feet.
Hopkins and Gilliatt [32] examined nerve conduction velocities and 
muscle action potentials of baboons treated with acrylamide. It appears 
that this study reports additional results from the experiment described 
above by Hopkins [31]. Conduction velocity and ascending nerve action 
potentials were measured in the median and anterior tibial nerves of the 
left limbs; all specimens for microscopic examination were taken from the 
right limbs. Muscle action potentials were recorded from the abductor 
pollicis brevis and extensor digitorum brevis. At acrylamide doses of 10 
or 15 mg/kg/day, the gradual development of limb weakness in the baboons 
was accompanied by a progressive reduction in the amplitudes of muscle and 
nerve action potentials. In the baboon receiving acrylamide at 15 
mg/kg/day, there was a progressive decline in amplitudes of muscle and 
nerve action potentials with an increase in latency period. Acrylamide 
administration was stopped on day 94; however, the amplitudes of action
potentials did not return to normal until 1 year later. The percentage 
reduction in the amplitude of the action potential was greater in thfp 
muscle of the foot than in that of the hand. These results supported the 
clinical observation that the disease was usually more severe in the lower 
than in the upper limbs. Reductions in nerve conduction velocities an4 
nerve action potential amplitudes were also observed in baboons treated 
with acrylamide at 10 mg/kg/day for an average of 110 days and measured 
within 3 weeks after the end of treatment. The percentage decreases in 
both velocity and amplitude were greater for sensory than for motop 
conduction in the median nerve. This deterioration sometimes continued for 
several weeks after acrylamide was discontinued.
Hopkins and Gilliatt [32] also studied the return of conduction 
velocity and action potential amplitude values to normal in one baboon 
treated with acrylamide at a dose of 15 mg/kg/day for 94 days and in two 
baboons given 10 mg/kg/day for 89 and 115 days. The baboon receiving J5 
mg/kg/day was severely affected and, while the amplitude of the nervte 
action potential was little changed until the end of the first year, it had 
returned to 80% normal by the end of the second year. Baboons receiving 
acrylamide at 10 mg/kg/day were less severely affected and the amplitude of 
the muscle action potential began to return to normal within 2-3 months, 
Hopkins and Gilliatt [32] also observed that a baboon treated with 
acrylamide at 20 mg/kg/day for 29 days remained severely paralyzed for 2 
days after treatment was stopped. Yet, the maximal conduction velocity in 
all the nerves examined was within the normal range and the action 
potential amplitude was only slightly reduced. The motor nerve conduction 
was normal at the same time that the animal was severely paralyzed
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suggested to these workers [32] that damage to the CNS also had occurred.
Bradley and Asbury [33] studied the effects of acrylamide added to 
the drinking water at a concentration of 250 ppm on 26 young adult female 
mice of BALB c Gn/J X SJL/J and SJL/J strains. Two mice from each strain
were used as controls. Animals drank the treated water ad libitum for 45
days. Pairs of animals were selected at random and killed at 23, 30, 35, 
40, 45, 50, 55, 60, 90, 120, or 165 days after the first exposure. The 
brain, spinal cord, sciatic nerve, and hamstring and gastrocnemius muscles 
of the mice were examined microscopically. No animals died during 
treatment with acrylamide at this dose. The first observed abnormality, 
difficulty in grasping and walking along the edge of the cage, appeared 
after 20 days of acrylamide administration, and by day 25, all animals 
either appeared unaware of the position of their hindlimbs or dragged their
feet when walking. After 35 days, the mice had lost some weight and hair.
Within 5 days of the withdrawal of acrylamide on day 45, the mice had 
gained some weight and their gait had improved. However, some signs of 
acrylamide poisoning persisted even 20 days after the withdrawal of 
acrylamide, as measured by the position of the lower limbs. Degenerating 
myelinated fibers were occasionally present in the sciatic nerve of mice 
killed 23 days after commencement of acrylamide and the proportion of such 
fibers increased with the duration of treatment. Multiple sections of the 
spinal cord showed no differences between acrylamide-treated and control 
mice. The results of microscopic studies of brain tissue were not 
mentioned. The hamstring and gastrocnemius muscles appeared wasted, 
although microscopic examination revealed only a slight increase in the 
number of areas of segmental necrosis and regeneration when compared with
control mice.
Hamblin [14] briefly described the effects on the growth of albino 
rats given acrylamide in the diet (10, 50, 100, or 300 ppm). No effects 
were reported at the 10- and 50-ppm levels. Diets containing 100 and 300 
ppm of acrylamide produced growth retardation within 6 and 4 weeks, 
respectively.
Fullerton and Barnes [27] studied the effects of acrylamide on 6- to 
8-week-old male albino rats. The animals were fed diets containing 100, 
200, 300, or 400 ppm of acrylamide. According to the authors [27], these
represented daily intakes of about 6-9, 10-14, 15-18, or 20-30 mg/kg,
respectively. Control rats received a similar diet without acrylamide. 
Rats on the acrylamide diets developed slight leg weakness as follows: at
400 ppm after 3 weeks, at 300 ppm after 4 weeks, at 200 ppm after 12 weeks, 
and at 100 ppm after 40 weeks. Severe leg weakness developed in all except 
the 100-ppm rats on continuation of dietary treatment; the slight leg 
weakness observed at week 40 did not increase during the remaining 8 weeks 
of the experiment. The only macroscopic findings at necropsy were wasting 
of the hindlimb musculature and distended urinary bladders in all rats. 
Axons and myelin sheaths of the sciatic, tibial, median, and ulnar nerves 
examined microscopically at necropsy showed extensive degeneration in the 
peripheral nerves of all the clinically affected animals. Microscopic 
examination of kidney, spleen, pancreas, adrenal, lung, brain, and spinal 
cord tissues showed no abnormalities.
McCollister et al [34] studied the effects of acrylamide given at low 
concentrations in the diet. Groups of 10 male and 10 female 8-week-old 
rats of the Dow Wistar strain were maintained on diets containing 3, 9, or
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30 ppm acrylamide for 90 days, and then killed and necropsied. As judged 
by their appearance, behavior, growth, mortality, organ weights, and 
microscopic examination of tissues, there was no evidence of adverse 
effects in either male or female rats. No signs of neurotoxicity were seen 
in two other groups of animals maintained on diets containing either 70 or 
110 ppm of acrylamide for 189 days. In the same experiment, McCollister et 
al [34] also studied the effects on male and female rats of acrylamide 
given at high concentrations in the diet. At a 300-ppm acrylamide dietary 
level, the rats began to show loss of control of the hindquarters after 21 
days. By day 42, all 10 males and 6 of 10 females were dead. Loss of 
hindquarter control was seen at 14 days in rats maintained at a diet 
containing 400 ppm of acrylamide. According to the authors [34], doses of 
3, 9, 30, 70, 90, 110, 300, and 400 ppm of acrylamide in the diet were 
equivalent to 0.3, 0.9, 3, 7, 9, 11, 30, and 40 mg/kg/day, respectively.
In a 1-year feeding study on cats by McCollister et al [34], 
different concentrations of acrylamide were mixed with feed to deliver 
total calculated daily doses of 0.03, 0.1, 0.3, 1, 3, or 10 mg/kg. The 
acrylamide diets were fed to two cats for 5 days/week at each dose. Cats 
fed 10 mg/kg/day developed signs of neurotoxicity, definite weakness in the 
hindquarters by day 26, and were unable to stand by day 52. One of the two 
cats was then killed; the other, taken off the acrylamide diet, recovered 
completely 53 days later. The two cats receiving acrylamide at 3 mg/kg for 
1 year survived to the end of treatment, but started showing twitching 
motions of the hindquarters by 26 days and signs of hindleg weakness by 68 
days; the latter persisted for a further period of 299 days. One of two 
cats receiving the 1-mg/kg dose for 1 year showed some twitching in its
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hindquarters by 26 days and signs of hindleg stretching when walking by 240 
days. In the remaining three dosage groups (0.3, 0.1, and 0.03 mg/kg),
five of the six cats died by day 106 from disease not attributable to 
acrylamide [34]. No toxic effects were seen in the only surviving cat (0.3 
mg/kg) at the end of the study. Hematologic tests (not specified), blood 
clotting times, and blood cholinesterase activities in cats treated at 3, 
1, or 0.3 mg/kg/day were not affected. Microscopic examination showed no 
evidence of adverse effects on central nervous tissues (brain and spinal 
cord) in any of the animals receiving acrylamide at any dose, including 10 
mg/kg/day.
Leswing and Ribelin [35] studied physiologic and pathologic changes 
in 11 young adult cats administered acrylamide orally. Acrylamide was 
mixed in the diet to deliver a calculated dose of 20 mg/kg/day. Within 2-3 
weeks, the cats showed slight weakness of the hindlimbs which progressed at 
variable rates to paralysis of the hindlimbs. Atrophy of the thigh and leg 
muscles was noticeable in severely paralyzed cats, and a few cats also had 
weakness of the forelimbs. The authors [35] reported that the cat cries 
became coarse, indicating possible involvement of the laryngeal nerves. 
Cats showed marked improvement when returned to their normal diet. 
Hindlimb strength was regained within 2-3 weeks, but complete recovery took 
several months and was directly related to the severity of the involvement. 
Microscopic examination of the nerves revealed degeneration of the myelin 
and axons of all four limbs. There was a suggestion of actual axon loss in 
the distal third or fourth portion of the tibial nerve fibers. Atrophy was 
evident grossly in nearly all muscles of the caudal limbs; however, 
microscopically, it was marked only in the digital muscles.
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Leswing and Ribelin [35] also measured peripheral nerve conduction 
and nerve and muscle action potentials in cats and monkeys that had severe 
neurotoxic effects from acrylamide treatment. The cats were administered 
acrylamide at 20 mg/kg/day in their diet. Four monkeys were given 
acrylamide at 20 mg/kg/day, injected into bananas, for 8 weeks. The dose 
was then increased to 30 mg/kg/day. Acrylamide-treated animals required 
higher applied voltages to stimulate the nerve, and most had greatly 
reduced muscle and nerve spike amplitudes. Conduction velocity was reduced 
from preexposure levels in sciatic and tibial nerves by an average of about 
29% in the cat and 24% in the monkey. "Substantial improvement" in 
conduction velocity was seen in both species on partial clinical recovery.
Schaumburg et al [36] studied ultrastructural changes in the nervous 
system of two cats given acrylamide at a dose of 3 mg/kg/day in drinking 
water. One cat received acrylamide for 252 days and the other for 294 
days. Onset of gait disorder was noted after 70 days in one cat and after 
163 days in the other cat. Hindfeet drop and distal muscle weakness were 
seen within 7 months. Tissues biopsied from the hindfeet after completion 
of the study showed a loss of all types of myelinated fibers in distal 
nerves. Only a few small and large myelinated nerve fibers were seen in 
plantar nerve twigs and most of the fibers were completely degenerated 
(bands of Bungner). Many unmyelinated nerve fibers were present. Most of 
the muscle fibers were vacuolated, shrunken, and had irregular borders—  
changes that the authors [36] considered secondary to denervation.
McCollister et al [34] also carried out a 1-year feeding study in 
female monkeys. One monkey was used at each dosage (0.03, 0.1, 1, 3, or 10 
mg/kg/day, 5 days/week). Two monkeys received the 0.3-mg/kg dose and two
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monkeys served as controls. The animals at the 10- and 3-mg/kg levels 
received their daily doses by intragastric administration of aqueous 
solutions of acrylamide. The other monkeys ate bananas injected with 
acrylamide given to them in the morning before any otbfer food. The monkey 
on the 10-mg/kg dose showed some weakness of the hindquarters by day 48 and 
extreme weakness by day 69. The animal was transferred to a control diet 
on the 70th day and recovered completely 54 days after acrylamide was 
discontinued. The monkey fed 3 mg/kg of acrylamide did not show any loss 
in body weight. Neurologic examinations of this animal sometimes showed 
either knee jerk or pupillary reflexes that were somewhat sluggish when 
compared with the response of the controls. The authors [34] considered 
these responses as insignificant. "Terminal hematologic examinations" 
(unspecified) at 1 year showed no abnormalities. At autopsy, gross 
examination of the animal revealed no abnormalities. Liver and kidney 
weights were normal. Microscopic examination of the liver and kidney also 
showed no significant adverse effects on cells of these tissues. 
Microscopic examination of the brain and spinal cord showed no 
abnormalities attributable to acrylamide. The monkeys on other dose 
regimens showed no adverse effects as measured by growth, general 
appearance, behavior, periodic neurologic examinations, liver and kidney 
weights, gross necropsy, and microscopic examination of the tissues.
(b) Dermal and Eye Studies
Hashimoto and Ando [37] studied the. dermal penetration of acrylamide 
in rabbits. A single application of acrylamide as a 10-30% aqueous 
solution penetrated the skin rapidly and appeared in the blood both as free 
compound and bound to proteins (mainly hemoglobin). Twenty-four hours
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later, the concentrations of acrylamide in tissues (unspecified) were 
higher than in the blood. Seven successive applications of 30 minutes each 
day progressively increased the blood and tissue concentration of 
acrylamide. Autoradiographs showed that 14C-acrylamide concentrated around 
hair follicles. No quantitative data were given.
McCollister et al [34] investigated the possibility of skin 
irritation from acrylamide by applying an unspecified quantity of 10% 
aqueous solution to the ear and to the shaved intact abdominal skin of a 
rabbit. Applications to the ear and abdomen were repeated 10 times over a 
period of 2 weeks. In another experiment, an abraded area of the shaved 
belly was treated with a 10% aqueous solution of acrylamide for 3 
consecutive days. No significant responses were observed except in the 
case of animals whose skins were abraded, which only showed a very slight 
reddening and slight edema that healed later. A 12.5% aqueous solution of 
acrylamide was applied to the skin of 12 rabbits and held in place with the 
aid of an impermeable sleeve for a 24-hour period. Two rabbits each 
received dermal applications of 0.063, 0.126, 0.5, and 1.0 g/kg of the 
acrylamide; four animals were treated with 0.252 g/kg. Only one rabbit 
that received the 1.0-g/kg application died within 2 days. Slight weight 
losses and reddening of the skin were noted in both rabbits treated with 
0.5 g/kg of acrylamide. No other effects were observed in any of the other 
rabbits.
The effects of eye contact with 10 and 40% aqueous solutions of 
acrylamide were also studied by McCollister et al [34]. The solution was 
instilled into the right eye of a rabbit and washed within 30 seconds with 
a stream of water for 2 minutes. The left eye was treated with the same
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amount of acrylamide solution but left unwashed. The eyes were examined 
with and without fluorescein staining, 2-3 minutes, 1 hour, and 24 hours
later for conjunctival and corneal responses. The 10% aqueous solution
caused signs of slight pain and slight conjunctival irritation immediately 
after contact, but the conjunctiva was completely normal within 24 hours. 
No injury to the cornea was reported. The application of the 40% aqueous 
solution of acrylamide to the unwashed eye caused signs of moderate pain, 
slight conjunctival irritation, and corneal injury. Although the 
conjunctival irritation was slow to heal, corneal healing was complete 
within 24 hours. Signs of moderate pain and slight conjunctival 
irritation were observed in the washed eye after administration of the 40% 
solution; however, there was no corneal injury, and the conjunctival 
irritation was nearly healed at 24 hours.
(c) Parenteral Studies
Hashimoto and Aldridge [38] studied the effects of acrylamide on body 
weights of male Porton-strain albino rats weighing about 200 g. Acrylamide 
was injected ip, twice a week, for 1 month. At 32 days after the first
injection, there was a 28% reduction in body weight in rats injected with
50 mg/kg; those injected with 100 mg/kg showed a weight reduction of 63%. 
Rats in both groups were ataxic after 2 weeks.
Suzuki and Pfaff [39] studied the effects of acrylamide in white 
Osbome-Mendel strain suckling and adult rats. One group consisted of 30 
suckling (1-day-old) rats weighing 5-8 g and the other of 28 adult rats 
weighing 150-300 g. The animals received ip injections of 50 mg/kg of 
acrylamide in saline, three times a week, for up to 18 injections; two 
additional adult rats each received a total of 26 injections. Controls
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were injected with saline only. Suckling rats, both experimental and 
control, gained weight normally until tlieir fifth or sixth injection, when 
weight gains of the ar.rylamide-injected animals slowed down. Slight 
weakness of the hindlimbs, noticeable in some of the young animals after 
five or six acrylamide injections, became more pronounced until the rats 
could no longer stand. In contrast to the results obtained In suckling 
rats, the body weights of the adults did not change. Weakness of the 
hindlimbs, noticeable after 7 or 8 injections, was followed by complete 
paralysis after 15-17 injections. At this time, wasting of the musculature 
of the hindlimbs was prominent. Weakness of the forelimbs was also noted 
in some rats. In the animals for which acrylamide treatment was terminated 
after the 16th injection, weakness of the extremities persisted for about 1 
month but, in animals given 26 injections, it persisted for about 2 months. 
Animals with clinical signs of neuropathy showed prominent distention of 
the urinary bladder in pups and adults at autopsy. The other organs were 
congested, but otherwise normal.
Suzuki and Pfaff [39j observed on microscopic examination occasional 
myelin figures in Schwann cells and enlarged fibers within the sciatic 
nerve and their distal branches in aciylamide-treated suckling rats after 
the fourth injection. These changes became prominent after eight 
injections and myelin degeneration was observed after 12-14 injections. In 
adult rats, both myelin and axonal degeneration were prominent after 15 
injections. According to the authors [39], rats which received 26 
injections showed "severe axonal loss" in both the proximal and distal 
portions of the sciatic nerve, but tills loss was more severe in the distal 
portions. In addition, the authors [39] reported an increased number of
Schwann cells, many of which had an abnormally high number of myelin 
figures in their cytoplasm. Light microscopic examination of sections of 
cerebrum, cerebellum, spinal cord, and brain stem showed degeneration of 
the spinal cord white matter and the presence of axonal spheroids in the 
cuneate nuclei of the medulla oblongata. No other CNS abnormalities were 
observed in adult rats. Hematoxylin and eosin-stained sections of lung, 
liver, spleen, pancreas, kidney, and adrenal showed no abnormalities.
With electron microscopy, the authors [39] found that the most common 
feature in suckling rats given nine injections of acrylamide was axons 
filled with fine filaments. Very few changes were noted in the adult rats 
killed after 10 or 12 injections. Many axons of the sciatic nerve were 
filled with neurofilaments; however, the myelin sheaths appeared normal. 
In addition to accumulations of neurofilaments, degeneration of axons and 
myelin sheaths was observed in adult rats receiving 15-18 injections. 
Sciatic nerves and their branches in adult rats which had received 26 
injections had numerous Schwann cells and macrophages containing many 
myelin figures and fat droplets but very few myelinated fibers. There were 
many Schwann cells in the sections, but few of these sections contained 
axons. Microscopic examination of the nerves of adult rats killed 20 or 30 
days after the last injection showed numerous axonal sprouts growing within 
the Schwann cells. Suzuki and Pfaff [39] concluded that, since 
degenerative changes of sciatic nerve axons seen only in adult rats in 
advanced stages of neuropathy were also frequently observed in suckling 
rats at the onset of paralysis, the peripheral nerves of suckling rats were 
more susceptible to acrylamide than were those of adults. The authors [39] 
suggested that the higher susceptibility of suckling rats could be a result
of the incomplete development of the barrier system of peripheral nerves.
Spencer and Schaumburg [40] examined the spatial-temporal 
distribution of hindlimb peripheral nerve degeneration in rats injected 
with acrylamide. Acrylamide, dissolved in saline, was administered daily 
by subcutaneous injection to 10 young-adult Spraque-Dawley rats in amounts 
of 10-60 mg/kg for 4-40 days. Sixteen age- and weight-matched rats were 
used as controls. The rats were killed before they developed signs of 
obvious hindlimb weakness. Nerve fibers separated from various sites in 
the sciatic, tibial, and plantar nerves were examined by light and electron 
microscopy. The large diameter fibers supplying the calf muscles and the 
long sensory fibers supplying the digits of the paws degenerated first. 
Degeneration of nerve fibers supplying the flexor digitorum brevis muscle 
occurred later. The findings from the electron microscopic examination 
showed accumulation of neurofilaments, abnormal mitochondria, and 
honeycombed, interdigitated Schwann cell-axon networks.
Kuperman [41] studied the neurotoxic effects of acrylamide on cats. 
Acrylamide was administered by various routes (iv, ip, im, oral, or 
subcutaneous) in daily doses of 1, 2, 5, 10, 15, 25, 40, or 50 mg/kg.
Groups of 3-11 cats were used at each level. Effects of chronic poisoning 
from acrylamide, as measured by the development of ataxia, appeared at 
identical dose levels and after equivalent latent periods irrespective of 
the route of administration, whether iv, ip, im, subcutaneous, or oral. 
The length of the latent period from the start of the treatment was 
inversely related to the amount of the dose and varied between 125 days 
with 1 mg/kg and 2 days with 50 mg/kg. In this study [41], the average of 
the doses that killed eight cats was 320 mg/kg. Microscopic findings in
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brain and spinal cord were normal.
McCollister et al [34] also studied the effects of acrylamide on one 
monkey given two ip injections 24 hours apart at doses of 100 mg/kg. 
Severe weakness was seen 24 hours after the second injection, and the 
monkey died on day 3. The findings from gross examination were congested 
lungs and kidneys and areas of necrosis in the liver. Microscopic 
examination of the kidneys showed degeneration of the convoluted tubular 
epithelium and of the glomeruli with albuminous material in the capsular 
space. Fatty degeneration of the liver was confirmed by the findings from 
the microscopic examinations.
Several investigators [36,40,42-46] have examined an acrylamide- 
induced degeneration of nerve fibers which begins in the distal portion of 
the fiber and proceeds slowly toward the cell body. This process, known as 
the "dying back" phenomenon, is a nonspecific type of nerve fiber 
degeneration that occurs simultaneously in the central and in the 
peripheral nervous systems. The nerves that are most commonly affected are 
those with the longest and largest axons. Sumner and Asbury [45]
administered an acrylamide solution (100 mg/ml) by subcutaneous injection 
at a daily dose of 10 mg/kg to healthy adult cats of both sexes (number 
unspecified). Electrophysiologic measurements were carried out at various 
stages from 21 to 67 days after the start of the treatment. The first sign
of neuropathy was slight hindleg ataxia, usually seen at about day 20 of
treatment. The acrylamide-treated animals were divided into three groups, 
ie, A, B, and C. Group-A cats (21-34 days) had mild hindlimb ataxia.
Group-B animals (38-44 days) had moderately severe hindlimb ataxia and
depressed or absent Achilles tendon jerks. Group-C animals (47-67 days)
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had extreme hindlimb ataxia that made walking very difficult. Achilles 
tendon jerks were absent in cats in this group. Conduction velocities were 
measured in a total of 1,001 afferent fibers isolated from animals in the 
three groups. All afferent fibers of the medial gastrocnemius nerve were 
conducted at 72-126 meters/second (Group-I velocity) or 24-72 meters/second 
(Group-II velocity). Maximal conduction velocities were similar in all 
three populations, but peak Group-I velocities were 108-114, 96-102, and 
84-90 meters/second in groups A, B, and C, respectively. Many single 
fibers, when isolated, did not respond to electrophysiologic stimulation 
normally adequate for stretch receptors; these were termed nonresponsive 
units. In group-A animals, 10% of the fibers (38/366) were nonresponsive. 
In group B, the proportion of nonresponsive units increased to 68% 
(215/315). In group-C cats, 89% (285/320) of the fibers were
nonresponsive. Sumner and Asbury [45] thus concluded that the number of 
nonresponsive single units isolated by systematic sampling of dorsal root 
filaments correlates well with the clinical severity of the neuropathy. 
They [45] also concluded from the similar maximal conduction velocities in 
all three groups that acrylamide produced no significant slowing of the 
conduction velocity in individual functioning fibers between the 
stimulating and recording electrodes.
At the end of each experiment and before the animal was killed, the 
medial gastrocnemius muscle and nerve were dissected free and fixed for 
microscopic examination. Microscopically, no nerve fibers were observed to 
have been lost or to have broken down in the medial gastrocnemius nerve 
before 55 days of acrylamide treatment; however, after 55 days, nerve 
breakdown ranged from 0 to 55% or more. The authors [45], in agreement
with Schaumberg et al [36], found that the muscle spindle nerve terminal 
was vulnerable to acrylamide. According to the authors [45], the results 
presented in this study indicated that interruption of nerve function may 
have been well advanced before any nerve fiber degeneration had occurred in 
nerve trunks. Hence, determination of conduction velocities would not have 
shown any abnormalities until nerve fiber degeneration had proceeded toward 
the cell body to the point at which the stimulating electrode had been 
placed.
Kaplan and Murphy [47] studied the influence, of age on rotarod 
performance of male Holtzman rats treated with acrylamide. The rotarod 
test procedure involved the use of a partitioned enclosure containing a 
floor that could be electrified and a rod which turned at 8 rpm. Rats were 
trained to maintain their balance on the rod throughout three 2-minute 
trials. A rat that fell during any two of the three trials failed the 
test. Four groups of 12 rats each (5, 7, 11, and 14 weeks of age) were 
administered acrylamide ip at a dose of 50 mg/kg/day until all the rats in 
the respective age group failed the test. The onset of, duration of, and 
recovery from acrylamide poisoning were measured by rotarod performance; 
body weights were also recorded. Small reductions in body weights or 
slower-than-expected growth rates were observed during the administration 
of acrylamide for 18-22 days. The means for the onset to failure were 7.3, 
6.4, 5.5, and 5.3 days, and the means recovery were 19.2, 15.6, 13.8, and
14.8 days for 5-, 7-, 11-, and 14-week-old rats, respectively. Thus, the 
delay in onset to failure was longer in younger animals; however, once 
impaired, they required a longer time to recover.
48
Prineas [42] employed light and electron microscopy in his 
observations on uhe tissues of cats treated with acrylamide. Acrylamide, 
10 mg/kg, was administered daily by subcutaneous injection to five cats of 
both sexes weighing between 2.5 and 4 kg. One cat was killed 11 days after 
commencement of the injections but before the onset of neurologic signs. 
The animals developed neurologic signs between days 17 and 22 and were 
killed 22-49 days after injections were begun. The finding from light
microscopic examination of nerves from the cat killed on day 22 were
fragmented axons and myelin-ovoid formations in the intramuscular nerves 
and in the tibial nerve. Specially prepared sections of the upper cervical 
cord from cats examined at 32 or more days after commencing the injections 
showed degenerating myelin sheaths in the spinocerebellar tracts, in the
gracile tracts, and in the white matter next to the anterior fissure; also,
electron microscopy of occasional fibers in the tibial nerve showed 
increased numbers of neurofilaments. By day 22, however, a majority of the 
large-diameter fibers showed an increase in the number of neurofilaments. 
Myelin degeneration was usually evident by 49 days, first appearing at the 
nodes of Ranvier. In all animals treated with acrylamide for 32 days, the 
cell bodies in the dorsal root ganglia showed some loss of the normal 
parallel arrangement of granular endoplasmic reticulum, breakdown of 
polyribosomes with release of ribosomes into the cytoplasm, and an increase 
in the amount of electron-dense material in the cytoplasm. Similar changes 
were also found in the anterior horn cells. Other changes included 
striking changes in nerve fibers and terminal buttons in the anterior 
spinal gray matter at the SI level. Small myelinated fibers frequently 
contained excessive numbers of neurofilaments which appeared to distend the
fiber in some instances. Between 5 and 15% of the terminal buttons were 
enlarged and contained excessive numbers of neurofilaments. Thus, this 
study [42] demonstrated structural damage in the distal CNS tracts of cats 
with signs of acrylamide poisoning.
Schaumburg et al [36], using techniques similar to those of Prineas 
[42], examined the early pathologic events in terminals of sensory and 
motor nerve fibers in the paws of cats treated ip with acrylamide. Two 
groups of animals were used for these parenteral studies. Five cats were 
injected with 10 mg/kg/day of acrylamide in an aqueous solution for 7-32 
days; another five cats received 10 mg/kg/day, alternating with 20 or 40 
mg/kg/day, either in interrupted or steady sequences. Six cats were used 
as controls. Tissues of acrylamide-intoxicated cats were obtained before 
and after total body perfusion with fixatives. With the cats under general 
anesthesia, biopsies of hindfeet toepad pacinian corpuscles, plantar 
lumbrical muscle, flexor digitorum brevis muscle, and twigs of the medial 
plantar nerve were performed and the tissues were examined under light and 
electron microscopy. The authors [36] observed that cats receiving 10 
mg/kg/day developed a weaving gait, thought to be secondary to hindlimb 
unsteadiness, within 13 to 15 days. This evolved into a gross truncal 
ataxia. In the second group of animals, who received acrylamide at more 
than 10 mg/kg/day, a rapid and irregular head tremor was noted 
occasionally. After 28 days on the 10-mg/kg/day dose or 15 days on the 
higher doses, the cats were barely able to walk; however, foot drop and 
muscle wasting were not observed at this time. The authors [36] reported 
that the axons of pacinian corpuscles began to degenerate before sensory 
nerve terminals supplying muscle spindles. Pacinian corpuscles are
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important to the animal's sense of position and they degenerated before the 
adjacent motor nerve terminals. These authors [36] concluded that sensory 
changes precede motor changes in the cat and that pathologic findings 
precede the occurence of clinical signs. They [36] also concluded that, in 
the dying-back phenomenon produced by acrylamide, changes occurred first in 
the distal parts of axons but not necessarily at the nerve terminal.
(d) Mechanism of Action
Various theories are provided in the literature explaining the
pathogenesis of selective axonal lesions from acrylamide. One explanation 
is that acrylamide interferes with the metabolic pathways of the nerve cell 
body which gradually fail in their functions to provide nutrient material
for the axon [48]. This leads to a depletion in the amount of material
reaching the distal regions of axons where degeneration begins. Another 
hypothesis suggests that acrylamide interferes with the intracellular 
transport system by which substances, assembled in the neuron cell body, 
are transported along the axon [49]. A third theory [44,50] notes that
acrylamide may have local toxic effects along the entire axon and that 
axons are more vulnerable than the cell bodies [42].
Interruption of transport of proteins along axons could result in the 
breakdown of the axons. To test this hypothesis, Pleasure et al [49] 
measured flowrates of newly synthesized proteins within sensory and motor 
axons of 12 healthy cats for comparison with those in 9 cats showing 
neuropathies induced by acrylamide at a dose of 20 mg/kg orally for 5 
days/week. Axonal degeneration, predominantly distal, was found in 
hindlimb nerves after neurologic signs had appeared but no alterations in 
the cell bodies of motor or of sensory neurons were evident. The flowrates
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of axonal proteins in motor and in sensory nerves were determined in nine 
cats, including two controls, at intervals from 4 hours to 2 weeks after an 
ip injection of 3H-L-leucine. One day after injection of tritiated 
leucine, the radioactivity in the ventral roots of cats in both the control 
and acrylamide-treated groups was maximal adjacent to the spinal cord, 
while maximal radioactivity in the dorsal root bordered the ganglion. In 
acrylamide-treated cats killed 2 or more days after receiving the isotope, 
maximal radioactivity in all seven cats remained at the border of the 
ganglion in the dorsal root and in five of the seven at the edge of the 
spinal cord in the ventral root. Pleasure et al [49] demonstrated the 
existence of a protein fraction moving along axons from motor and from 
sensory neurons at about 1.5 mm/day. Evidence of such transport was absent 
in most of the cats made neuropathic by acrylamide. The authors [49] 
indicated that the absence of a migrating protein peak in acrylamide- 
induced neuropathy may have been from inhibition of protein synthesis or a 
defect in the transport mechanism. The accumulation of radioactivity close 
to the cell bodies in cats treated with acrylamide suggested that protein 
synthesis had occurred and that the defect was in the transport process 
itself.
In a subsequent report, Bradley and Williams [51] studied both the 
fast and slow components of axonal transport from dorsal root ganglia along 
the proximal regions of the sciatic nerve of cats with mild-to-moderate 
degrees of acrylamide neuropathy. Young cats of mixed breed, 1.5-4.25 kg 
in weight, were given acrylamide orally at a dose of 20 mg/kg/day, 5 
days/week. The dose of acrylamide was adjusted to induce mild-to-moderate 
incordination and weakness of the hindlimbs in 2-6 weeks. Cats were
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injected with 3H-L-leuc,ine in the seventh lumbar dorsal root ganglion only 
on one side. Control animals were injected with 3H-L-leucine only. Three 
control and three acrylamide-treated animals were killed 6 hours, 10 days, 
or 30 days after injection of the tritiated leucine. Contrary to the 
findings of Pleasure et al [49], the authors [51] found no difference in 
slow axonal transport between acrylamide-intoxicated and control cats. 
There was a decrease in the velocity of the crest of fast axon transport in 
the acrylamide-treated cats, but they [51] suggested that this reduction 
was unlikely to be responsible for the degeneration present in the distal 
portions of the axon.
Hashimoto and Ando [52] examined the effects of acrylamide on the in 
vitro incorporation of radioactive amino acids into the proteins of brain, 
spinal cord, sciatic nerve, and liver tissues. Eight-week-old male 
Sprague-Dawley rats were fed a diet containing 500 ppm of acrylamide for 4 
weeks and no acrylamide for the next 4 weeks. The control group was fed 
the untreated diet only. The animals given acrylamide began to show 
weakness of the hindlimbs at 2 weeks, slight disturbances in walking at 3 
weeks, and paralysis at 4 weeks. After removal of acrylamide from the 
diet, the paralyzed animals recovered in 5-6 weeks. The incorporation of 
14C-lysine into tissue proteins was studied at 1, 2, 3, 4, 6, and 8 weeks 
after acrylamide feeding was begun. No differences in the incorporation in 
the brain and liver slices of the control and acrylamide-treated rats were 
seen at any of these intervals. However, more radioactivity from labeled 
lysine was counted in proteins of the spinal cords of treated than of 
control rats after 4 weeks of feeding and the difference continued to 
increase, particularly in the lower cord, until 6 or 8 weeks. In the
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sciatic nerve, a slight decrease in radioactivity was noted after 2 or 3
weeks, but was followed by a larger increase beginning at 4 weeks.
The effects of acrylamide on the incorporation of 35S-methionine into 
proteins were studied at weekly intervals from weeks 2 to 6 of feeding 
[52]. The incorporation by the controls was highest at all times in the 
sciatic nerve followed by the liver, brain cortex, and spinal cord. A 
significant increase in incorporation was demonstrated at 6 weeks after 
start of the feeding in the spinal cord and sciatic nerve, but not in the 
brain or liver. In contrast to the results obtained with lysine, when
methionine was used, no decrease in radioactivity was seen in the sciatic 
nerve protein at the early stages. The early decrease in 14C-lysine
incorporation in the sciatic nerve may have been associated with the 
biochemical mechanism of neuropathy, such as interruption of the protein 
axoplasmic flow in nerve roots as postulated by Pleasure et al [49], and 
the decreased metabolism of proteins in the axons and Schwann cells. The 
increased incorporation of amino acids into the spinal cord during the 
recovery period may have been because of increased protein metabolism in 
the anterior horn cells, in which a large number of silver grains from
14C-lysine were visible in the autoradiograph. The increased incorporation 
of amino acids into the sciatic nerve during the later stages of neuropathy 
might have been related to the proliferation and increased metabolism of 
Schwann cells, in which many silver grains were demonstrated. Since amino 
acid incorporation in the brain and in the liver was not affected by 
acrylamide, these authors [52] suggested that the compound had a specific 
effect on the spinal cord and peripheral nerves.
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Hollinger and Rossiter [53], in their study on Wallerian degeneration 
of peripheral nerves, found that beta-glucuronidase activity in the sciatic 
nerve of 56 cats markedly increased during the regenerative phase of the 
injury. Kaplan and Murphy [47] measured sciatic nerve beta-glucuronidase 
activity in 24 acrylamide-treated rats. Male Holtzman rats, weighing 200- 
300 g, were administered acrylamide ip at a dose of 50 mg/kg/day for 8 
days. There was a slight but significant rise in beta-glucuronidase 
activity of sciatic nerves 1 week after the last dose of acrylamide;- the 
enzyme activity continued to increase, reaching a peak of 340% of the 
control values 3 weeks after the last injection. The greatest increase in 
enzyme activity occurred after apparent recovery from the neuromuscular 
impairment produced by acrylamide. The investigators [47] suggested that, 
if the acrylamide-induced increase of beta-glucuronidase activity in the 
peripheral nerve reflected peripheral nerve regeneration and hence 
incomplete healing, an increased sensitivity to acrylamide might 
have been anticipated during this period. Indeed, at 30 days, when 
beta-glucuronidase activity in the sciatic nerve of cats was 320% of the 
control values, rats were significantly more susceptible to acrylamide. 
The mean days of failure, as measured by a rotarod performance test, for 
rats retreated with 50 mg/kg/day of acrylamide and their age-matched 
controls were 2.5 and 4 days, respectively. Conversely, at 90 days, 
when beta-glucuronidase activity of the sciatic nerve was 155% of control 
values, no differences in rotarod performance between retreated rats 
and their age-matched controls were evident. If the increased beta- 
glucuronidase activity in the sciatic nerve observed after acrylamide- 
induced neuropathy reflects peripheral nerve regeneration, then the
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increased susceptibility of rats to retreatment with acrylamide suggests 
the addition of a new injury to a preexisting injury that is not 
functionally apparent.
Hashimoto and Aldridge [38] studied the distribution and excretion of 
acrylamide in rats. Six male Porton-strain albino rats weighing about 
200 g were injected iv with radioactive acrylamide at a dose of 100 mg/kg. 
The 14C-radioactivity was measured in the expired air and in the urine. 
About 6% of the injected dose was exhaled as carbon dioxide in the first 8 
hours; excretion was very low after that (reaching only slightly more than 
6% in 24 hours). Urinary excretion of the 14C-radioactive material was 
very rapid, 40% of the injected dose excreted over the first day and a 
maximum of about 65% reached by day 4; the excreted metabolites were not 
identified. The distribution of 14C-radioactivity was studied in whole 
blood, plasma, brain, spinal cord, sciatic nerve, liver, and kidney at 1, 
4, and 14 days after injection. At each of these intervals, the 
radioactive material was found in all tissues examined, with high counts in 
the blood. A considerable amount of radioactivity was present at 14 days; 
most of it was not extractable by 5% trichloroacetic acid and so was 
presumably protein-bound.
Edwards [54] recently reported on the half-life of acrylamide in the 
blood of male Porton-strain rats weighing 200 g. Acrylamide dissolved in 
0.9% saline was injected iv at a dose of 100 mg/kg. The drop in the blood 
concentration of acrylamide was exponential and its half-life was 1.9 
hours.
Kaplan et al [55] studied the effects of hepatic microsomal enzyme 
inducers on the functional neuronal deficit produced by acrylamide. The
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authors observed that pretreatment with either DDT or phenobarbital 
noticeably delayed the onset of neurologic deficit. The total dose of 
acrylamide required for 100% failure of control rats in rotarod performance 
tests was 360 mg/kg; it was 520 and 600 mg/kg for the DDT- and 
phenobarbital-pretreated animals, respectively.
Edwards [56] also investigated the effects of DDT and phenobarbital 
on acrylamide-induced neurotoxicity; however, the results obtained in this 
study were different from those reported by Kaplan et al [55]. Animals 
were fed a diet containing 500 ppm of acrylamide. Slight ataxia developed 
in the controls (receiving acrylamide only) and in both experimental groups 
after 8-10 days on the acrylamide-treated diet. All rats recovered at the 
same time after treatment. There were two major differences in the 
experimental procedures used by Kaplan et al [55] and by Edwards [56]. In 
the former study, acrylamide was given daily by single ip dose; in the 
latter, it was given in the diet. However, the calculated daily dose of 
acrylamide in the study by Edwards [56] was similar to that given by Kaplan 
et al [55]. The second major difference in the two studies was the method 
of assessing neurotoxicity. In the study by Edwards [56], it was 
subjective and depended upon personal observations, whereas Kaplan et al
[55] used the rotarod performance test which they claimed was more 
sensitive than subjective analysis.
Correlation of Exposure and Effect
Humans have been exposed to the monomeric form of acrylamide both in 
occupational [16-21,23] and nonoccupational [22] situations. Workers have 
been exposed in the manufacture of the acrylamide monomer from
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acrylonitrile acid hydrolysis [23]; in the handling of a 10% aqueous 
solution in a mine [16]; in the production of flocculators from the monomer 
[20]; in the use of a resin mixture that apparently contained residual 
monomer in sealing processes [17,18]; and in the production of polymers 
while manufacturing papercoating materials [21]. The exposure of a 
Japanese family to acrylamide-contaminated well water, which they drank, 
cooked with, and bathed in (the latter for a few days only) was the single 
nonoccupational incident [22].
In all of the occupational incidents [16-21,23], the dermal route of 
exposure was predominant, with some respiratory exposure and with slight 
oral ingestion possible through hand contamination [16-21,23]. An example 
of dermal exposure was one worker who repeatedly splashed a 10% aqueous 
solution of acrylamide on his unprotected hands, forearms, and face [16]. 
Other workers who were filling pumps or working in areas where there were 
leaks in the pressurized delivery system were splashed with a resin 
containing an unknown amount of monomers. In contrast to those exposures, 
workers in a flocculator plant where all skin contact was avoided exhibited 
no signs of intoxication [20]. The authors [20] also stated that the 
crystalline monomer was heavy (large particle size) and did not form stable 
aerosols. The vapor pressure of solid monomeric acrylamide is 0.007 mmHg 
at 25 C [1], equivalent to a saturation concentration of 27 mg/cu m, so 
acrylamide vapor may pose a hazard in confined or poorly ventilated spaces. 
The more likely inhalation ha ard from acrylamide solution is from 
aerosolization of the solution.
Although signs and symptoms that developed in some workers who were 
exposed dermally to monomeric acrylamide have been well documented [19-
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21,23], the exact time of the appearance of symptoms after dermal exposure 
was not. The times of onset that were reported varied from 4 weeks [20] to 
about 24 months [21] except for one worker [21] who was employed for 
approximately 8 years before symptoms appeared. Not all of the exposed 
workers had recognized adverse effects [16,19-21,23]. Initial symptoms 
after skin exposure were numbness [16,18,20-22], tingling (paresthesia) 
[18-22], and "tenderness to the touch," followed in days (or 1-2 weeks) by 
coldness of the hands and fingers, and less often of the feet and toes 
[16,18]. Concurrently, or occasionally somewhat later, excessive sweating 
[16-21], bluish-red skin on the hands [18-21,23], and peeling of the skin 
of the hands and less often the feet [16-21] were followed by fatigue and 
marked weakness of the limb muscles [16,19,20].
Skin absorption in mammals has been confirmed by Hashimoto and Ando 
[37], who found that absorption of 14C-acrylamide in rabbits was rapid. 
The 14C-acrylamide was found free in the blood and bound to protein, mainly 
hemoglobin, within hours of skin application, and in unidentified tissues 
in 24 hours. Successive dermal applications increased the blood and tissue 
levels. McCollister et al [34] also found that the rabbit skin absorbed 
acrylamide. They made dermal applications of 1 g/kg which killed one of 
two rabbits.
Many of the effects reported in humans have been confirmed in 
animals. Muscular weakness also occurred in rats [14,27], dogs [14], cats 
[34], monkeys [341, and baboons [31]. Weight loss was noted in humans 
[16,18-20], especially those who handled 10% aqueous solutions of 
acrylamide [16], rats [14,38,39], monkeys [34], and mice [33]. Sleepiness 
and lassitude preceded death in rats [14]; however, these effects were more
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evident in those humans who ingested acrylamide-contaminated water [22] 
than in those dermally exposed. Another manifestation, which occurred in 
adults who ingested acrylamide, was retention of feces and urine that 
resulted in constipation and overflow urinary incontinence [20,22], 
Distended urinary bladders were also reported in animals [27,34]. Reddened 
skin from dermal contact with acrylamide has been reported in humans [17] 
and in rabbits [34].
It is notable and in marked contrast to the reactions of those people 
who were occupationally exposed (mainly dermally) to acrylamide [17-20,23] 
that the initial complaints of those exposed by ingestion [22] were not 
directed toward the extremities or the skin. When symptoms of mild 
dysesthesia did occur by oral ingestion and probably also by dermal 
absorption, the three adults [22] had been hospitalized for emotional 
problems for 2-4 weeks.
Electromyography and nerve conduction studies were performed on 
humans before [21,23] and during [25] recovery from acrylamide 
intoxication. Muscle response to nerve stimulation was abnormal, 
indicating damage of distal nerve terminals [21]. Conduction velocity was 
affected in only a few units of each motor nerve [21,25]. Structural 
abnormalities were also found in the distal portions of the long nerves 
[25]. Because both the action potentials and conduction times in the 
sensory nerves were more extensively affected than in the motor nerves, the 
author [25] concluded that the sensory fibers were damaged earlier and more 
severely than the motor fibers.
Microscopic examination by Fullerton [25] of biopsied sensory nerves 
from two patients in the Garland and Patterson [20] study showed the
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presence of simultaneous degeneration and regeneration of the sensory 
nerves which seemed to have occurred before the onset of symptoms• 
Neuroanatomic and physiologic studies [39,41,42,47,49,52,53,55] on animals, 
performed on a much more extensive scale than in humans, confirmed these 
results. Excretion of 14C-acrylamide and the effects of hepatic microsomal 
enzyme inducers on the toxicity of acrylamide also have been studied. 
While these results have added to the information concerning the effects of 
acrylamide on various life processes, they do not describe the initial 
process whereby acrylamide produces peripheral neuropathy in humans and 
animals.
Other important and diagnostic manifestations of the acrylamide 
effect on humans are: dizziness [17,20,21,23]; vertigo [23]; positive
Romberg's sign and inability to stand on one leg [17,19-23]; slurring of 
speech [20]; confusion, insecurity, and bizarre behavior [22]; poor memory 
and orientation [22]; writing inability or difficulty [19]; muscle pain 
[18,20,21] ; adiadochokinesis [23,34]; gastrointestinal disturbance and 
dysphagia [18,23]; loss of temperature and touch and vibration senses 
[16,20-22]; dysarthria [20]; and paresthesia, dysesthesia, and 
hyperesthesia [21,22].
In summary, in the absence of pertinent exposure data, no useful 
correlation can be made between the type and extent of exposure and the 
degree of human intoxication produced by acrylamide in the industrial 
environment [16-21,23-25]. However, the signs and symptoms, results of 
general medical and neurologic examinations, and the treatment and cure or 
regression of reactions reported in humans [15-23], including the nerve 
conduction and microscopy studies [21,25], when compiled and summarized,
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are very valuable for the recognition of the sequence and characterization 
of adverse effects produced on humans by exposure to monomeric acrylamide. 
The animal studies also are pertinent in understanding human effects since 
they are very similar. In the single report of a nonoccupational episode 
[22] found, three of five family members were hospitalized after ingesting 
well water containing an acrylamide concentration of 400 ppm. Just how 
much each ingested is unknown. It is evident that effects on the CNS, 
rhinorrhea, and coughing were the first symptoms which were noticed by the 
people who ingested acrylamide, while those dermally exposed first noticed 
paresthesias, skin changes, and muscle weakness of the extremities. In all 
known recorded human cases of and in all types of exposures to acrylamide, 
persons recovered in 2 weeks-2 years (latter associated with peripheral 
nerve defects); most persons recovered in 1-12 months after cessation of 
exposure to acrylamide.
Carcinogenicity, Mutagenicity, and Teratogenicity
No reports which address the subject of possible carcinogenic, 
mutagenic, or teratogenic properties of acrylamide monomer were found.
Summary Tables of Exposure and Effect
The effects of dermal and oral exposures on humans to acrylamide that 
were presented in Chapter III are summarized in Table III-l. The effects 
of short- and long-term exposures on animals to acrylamide are summarized 
in Table III-2.
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TABLE III-l
SUMMARY OF EFFECTS OF ACRYLAMIDE EXPOSURE ON HUMANS
Duration
Number of and Route Ref-
Subjects of Exposure Observed Effects erences
3 - 2 4  mo
dermal and 
possible 
inhalation
Erythema, excessive sweating, muscu- 16-18, 
lar weakness Brinkley*
3 - 13 mo
dermal and 
possible 
inhalation
Loss of weight, anorexia 17-20,
23
4 - 7 mo
dermal and 
possible 
inhalation
Eye irritation, skin rash, fatigue, 16,19 
confusion
2 mo - 8 yr 
dermal and 
possible 
inhalation
Gastrointestinal upset 21
1 mo 
ingestion
Rhinorrhea, urinary and fecal reten- 22 
tion, ecchymoses
7 - 12 mo
dermal and 
possible 
inhalation
Vertigo, abnormal reflexes, emotion- 16,17, 
al changes 19,23
3 - 24 mo
dermal and 
possible 
inhalation
Ataxia, hypoesthesia 16-18
TABLE III-l (CONTINUED)
SUMMARY OF EFFECTS OF ACRYLAMIDE EXPOSURE ON HUMANS
Number of 
Subj ects
Duration 
and Route 
of Exposure Observed Effects
Ref­
erences
17 1 mo - 8 yr 
dermal and 
possible 
inhalation
Pain, tremor, desquamation, sen­
sory loss
16,17,
20,21
10 1 - 15 mo 
dermal and 
possible 
inhalation
Positive Romberg’s sign 17,19,
20,23
*From DR Brinkley (written communication, June 1976)
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TABLE III-2
SUMMARY OF EFFECTS OF ACRYLAMIDE EXPOSURE ON ANIMALS
Routes of Refer-
Exposure Species Dose and Duration Observed Effects ences
Dermal Rabbits 0.5 
24 hr
1.0 g/kg Edema, death 1/5 34
10% solution 
3 d
10% solution 
2 wk
On abraded skin, slight 34
reddening, edema
On shaved skin, no effects 34
Ocular " 10 and 40%
24 - 48 hr
Oral Rats 203 - 277 mg/kg
1 dose
Pain, conjunctival irrita­
tion
LD50, death 5/5
41
27,28,
34
50
1
- 126 mg/kg
- 15 d
100 mg/kg
3 d
0.3 - 11 mg/kg 
55 - 189 d
Lethargy, weakness, blad­
der distension
Death of most animals
No effects
29
14,27,
29
27,34
200 - 400 ppm Loss of motor control,
1 - 6 mo ataxia, leg weakness, pro­
gressive paralysis
100 ppm Growth retardation, leg
6 - 40 wk weakness
10 - 50 ppm No effects
6 wk
14,27,
29,34,
56
27,34
14
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TABLE III-2 (CONTINUED)
SUMMARY OF EFFECTS OF ACRYLAMIDE EXPOSURE ON ANIMALS
Routes of Refer-
Exposure Species Dose and Duration Observed Effects ences
Mice 170 mg/kg 
1 dose
LD50 14
I f 250 ppm 
45 d
Weight loss, ataxic gait 33
Rabbits 252 mg/kg 
1 dose
Death 4/4 34
f l 126 mg/kg 
1 dose
Death 1/4; tremors, pupil 
dilation
34
Guinea
pigs
252 mg/kg 
1 dose
Death 4/4 34
I f 126 mg/kg 
1 dose
No deaths, slight weight 
loss
34
Cats 1 - 20 
53 - 367
mg/kg 
d
Weakness, paralysis, 
twitching
35
I I 0.03 - 0, 
367 d
.3 mg/kg No effects 34
Dogs 5 - 100 
4 - 5
mg/kg
wk
Ataxia, sedation, weakness 14,21
I I 1 - 8 
4 - 19
mg/kg 
wk
No effects 14
Monkeys 10 - 30 
8 - 10
mg/kg
wk
Weakness, decreased nerve 
conduction velocity, mye­
lin and axonal degeneration
34,35
I I 0.03 - 3 
51 wk
mg/kg No effects 34
Rats 50 - 100 
4 - 6
mg /kg 
wk
Weight loss, paralysis, 
bladder distension, myelin
38,39
and axonal destruction
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TABLE III-2 (CONTINUED)
SUMMARY OF EFFECTS OF ACRYLAMIDE EXPOSURE ON ANIMALS
Routes of 
Exposure Species Dose and Duration Observed Effects
Refer­
ences
ip Monkey 100
2
mg/kg 
d
Lung and kidney congestion, 
liver necrosis, severe 
weakness, death
34
iv
M
50
4
mg/kg 
d
Death within 4 d 34
Subcu­
taneous
Cats 10
21
mg/kg
- 61 d
Ataxia, absent Achilles 
tendon jerks, interruption 
of nerve function
45
Oral
ip
iv
im
Subcu­
taneous
I f 1 - 50 mg/kg 
(duration not 
specified)
Ataxia, progressive weak­
ness, gradual blood- 
pressure drop to shock 
level; death of some ani­
mals
41
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IV. ENVIRONMENTAL DATA AND ENGINEERING CONTROLS
Sampling and Analytical Methods
During industrial operations, monomeric acrylamide may escape into 
the environment as both dust and vapor from the solid and as a mist from 
aqueous solutions [57]. Little or no information has been found in the 
published literature on sampling methods for either acrylamide dust or 
vapor. However, the major manufacturers and users of monomeric acrylamide 
have provided some insight into a few sampling procedures. A direct 
readout method for analysis of airborne monomeric acrylamide dust and vapor 
has not been found.
One method for the sampling of acrylamide dust involving the use of a 
portable pump with an 0.8-jum membrane filter (open face) at an air flowrate 
of 2-3 liters/minute has been recommended for breathing zone sampling [58]. 
The minimum sampling time at a concentration of 0.3 mg/cu m was 30 minutes. 
No information is available on different concentration ranges over which 
this method is applicable. Unless the membrane filter is properly stored 
after sampling either by refrigerating or in a sealed cassette, sample loss 
by sublimation [1] could cause an error. Also, sampling with a membrane 
filter does not collect the vapor portion of acrylamide in the air and 
tends to underestimate the total exposure.
Adsorption of acrylamide on silica gel has been used for personal and 
general air sampling [59]. Two silica gel tubes with small glasswool plugs 
on each end were connected in series to a sampling pump. The flowrate was 
adjusted at 0.05-0.20 liters/minute. Acrylamide collected on the silica 
gel was extracted with water [59] or methanol-water (80:20 V/V) solution
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[58] for analysis. There is insufficient information regarding 
concentrations that were tested, the concentration ranges over which this 
method is applicable, and a minimum sampling time. Although this method 
can be used for collection of acrylamide vapor, it probably does not
collect acrylamide particulates efficiently. In addition, glasswool plugs 
at both ends of the tube would probably collect some dust particles since 
they are inefficient filters. In any case, this system is not useful for 
collection of total acrylamide in air.
Another method of sampling for determination of acrylamide vapor in 
air was developed by using a midget fritted glass bubbler [60]. The 
bubbler was filled to the 20-ml mark with distilled water and air was 
passed at a flowrate of 1 liter/minute for 100 minutes. Data concerning 
concentrations of acrylamide in the air that were collected are not
available. However, the sampling adsorption efficiency of one bubbler with 
a flowrate of 1 liter/minute and a sampling period of 100 minutes was 
reported to be 98%, but without supporting data.
Midget impingers, as well as silica gel tubes, have been used to 
sample airborne dust and vapor of acrylamide [58,61]. Two midget 
impingers, each containing 15 ml of distilled water, were connected in 
series. The recommended sampling time was a minimum of 60 minutes with an 
air pump adjusted to a flowrate of up to 1.75 liters/minute [58]. It was 
indicated that this sampling method is applicable to any acrylamide monomer
which may be present in the air in an industrial environment [58]. It was
also stated that, since the sample size is essentially unlimited, the limit 
of detection of acrylamide in air is determined by the amount of 
interference present. Details such as efficiency of collection by the
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impingers and concentration ranges over which this sampling technique is 
valid were not given.
A variety of sampling methods have been discussed, such as the 
portable pump with a membrane filter, silica gel tube, midget fritted glass 
bubbler, and midget impingers. There is no one method that is uniquely 
applicable for collecting acrylamide aerosol and vapor. A membrane filter 
has been used to collect samples of acrylamide aerosol and the midget 
fritted glass bubbler has been used for determinations of acrylamide vapor 
in air. Silica gel tubes and midget impingers can be used to collect both 
dust and vapor with the latter method having less vapor loss. Therefore, 
despite the disadvantages of handling glassware and liquid solutions in 
field measurements, the sampling technique of using a midget impinger is 
recommended for personal breathing-zone sampling of airborne acrylamide 
dust and vapor to guard against losses attendant with filter sampling.
Samples of acrylamide in air have been analyzed by using 
spectrophotometry [62], gas chromatography [60,63], refractive index 
measurement [64], titration using bromate-bromide solution [65], thin-layer 
chromatography [63], direct current (DC) polarography [66], and 
differential pulse polarography (DPP) [67].
Mattocks [62] reported on spectrophotometric methods which involve 
the formation of pyrazoline by reacting monomeric acrylamide with 
diazomethane in a methanol-ether solution. The formed pyrazoline 
yields a bright yellow derivative with acidic Ehrlich reagent 
(4-dimethylaminobenzaldehyde) and a more stable, purple-colored complex 
with 4-dimethylaminocinnamaldehyde; the yellow and purple colors are 
measured at 440 and 538 nm, respectively. The working range for
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both assays was 0.2-2.0 ¡xg/ml of acrylamide. One disadvantage of these 
methods is working with diazomethane, a suspected carcinogen [62] which has 
to be redistilled shortly before use to eliminate impurities. In 
addition, the color formation in the reaction of pyrazoline and 
either 4-dimethylaminocinnamaldehyde or 4-dimethylaminobenzaldehyde is 
subject to interference from pyrroles, indoles and related compounds, 
aromatic amines, hydrazine, and carbonyl compounds.
Analysis of monomeric acrylamide solutions was also determined by 
measuring the refractive index of a sample solution at 35 C with an Abbe 
refractometer and converting the reading to percent acrylamide using a 
standard curve [64]. Duplicate determinations were within 0.4% and the 
method could be applied for an aqueous acrylamide solution range of 5-60%. 
The usual concentration range of acrylamide monomer solutions in previously 
discussed analytical procedures is much lower than 5% and lacks specificity 
and sensitivity for a determination of acrylamide at the environmental 
limit.
A more sensitive, but nonspecific, analysis of monomeric acrylamide 
solutions can be performed by a titrimetric method [65]. This method was 
based on the reaction of acrylamide with bromine which is obtained from an 
acidified bromate-bromide solution. The excess bromine was treated with 
potassium iodide which generates free iodine. The iodine was then titrated 
with thiosulfate to yield an indirect measure of acrylamide. Any reducible 
substance may interfere with this method. The titrimetric method gave a 
relative standard deviation of 0.1 and 0.01% for concentrations above and 
below 2% of acrylamide in solution, respectively.
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Acrylamide vapor in air was collected with a bubbler and subsequently 
analyzed by gas chromatography after formation of a 1,2-dibromopropionamide 
derivative [60]. This method was used over a concentration range of 0.005- 
0.160 mg/cu m over a 100-liter air sample. Contents of a bubbler diluted 
with sulfuric acid solution from a fritted glass midget bubbler containing 
monomeric acrylamide were brominated with excess bromine water, irradiated 
with UV light, and an ether extract was injected into a gas chromatograph 
and detected by electron capture. No information was reported on 
interferences. The conversion efficiencies from the monomer to the 
derivative are unknown. However, the concentration range was well within 
limits to test adequately for the Threshold Limit Value of acrylamide (0.3 
mg/cu m). Use of bromine water and UV irradiation to form the derivative 
along with the steps involved in sample preparation, such as the adjustment 
of pH and the extraction process, are disadvantages of this method, but 
they are within the technical capabilities of most laboratories.
Croll [63] determined the acrylamide content in polymers and 
copolymers by analyzing a methanol-water (80:20 V/V) extract with a gas 
chromatograph. A 20% W/W Carbowax 20 M on 60/80 mesh Chromosorb W-acid- 
washed, dimethyldichlorosilane column was used. The sensitivity of this 
method for acrylamide is 4 jug in 10 ml of methanol-water extract. Extracts 
from some of the polymers studied contained compounds (unspecified) which 
had similar retention times as acrylamide. Buildup of nonvolatile 
compounds in the injection zone affected the column performance. These 
compounds made discrete acrylamide determinations impossible without 
further purification of the extracts. Infrared spectroscopy and thin-layer 
chromatography were used to confirm that peaks from the gas chromatographic
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analysis tentatively identified as acrylamide were in fact from acrylamide. 
To prepare for infrared spectroscopy, a portion of the polymer extract 
equivalent to about 2 mg of acrylamide was evaporated to dryness onto 
potassium bromide and pressed into a disc. The infrared spectrum of this 
sample was so intense that other contaminants were obviously interfering. 
After the sample was separated by thin-layer chromatography and the 
acrylamide portion of the chromatogram removed with methanol, the potassium 
bromide disc prepared from the extract gave an infrared spectrum identical 
to that of the pure acrylamide standard. Direct infrared analysis is
subject to interferences from unspecified contaminants from the polymers. 
Another disadvantage of the method is the large amount of acrylamide
required for measurement.
Thin-layer chromatography was used to evaluate the acrylamide content 
in polymers extracted with acetone or a chloroform-methanol (80:20 V/V) 
solution [63]. Acrylamide was determined chromatographically on silica gel 
plates. The spots on the plates representing acrylamide were made visible 
by spraying with either a fluorescein-bromine reagent or 0.01% potassium 
permanganate reagent which produced yellow spots on a pink background 
plates for samples containing as little as 0.25 fig of acrylamide. The
eluates of the sample scraped from the plates were analyzed by gas
chromatography giving a 90% recovery of the acrylamide standard.
MacWilliams et al [66] used direct current (DC) polarographic 
techniques for analysis of monomeric acrylamide in polyacrylamides. The 
procedure involved the use of a mixed methanol-water (80:20 V/V) solution 
for the extraction of the monomer from the polymer. The extract was then 
polarographically analyzed using the supporting electrolyte tetra-n-
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butylammonium hydroxide. The concentration range over which this method is 
sensitive was 0.01-0.5% acrylamide in polyacrylamides. The authors were 
able to detect acrylamide concentrations as low as 100 ppm. As long as 
potentials were carefully corrected for cell resistance and the acrylamide 
concentration was kept below 0.5 mg/ml in the extract, the DC polarographic 
technique was reliably accurate. Low monomer concentrations made the 
acrylamide wave difficult to resolve from the background.
Betso and McLean [67] adopted the polarographic technique to detect 
and determine monomeric acrylamide in polyacrylamides by using differential 
pulse polarography. The extraction procedure was similar to that of 
MacWilliams et al [66] except that the electroanalytical chemical 
instrumentation has improved since 1965. A methanol-water solvent extract 
of the polyacrylamides was treated with an ion-exchange resin to remove 
interfering cationic and anionic species. After appropriate pH 
adjustments, the resin-treated extract was polarographically analyzed with 
the supporting electrolyte, tetra-n-butylammonium hydroxide. The 
polarographic cell consisted of a dropping mercury electrode as the cathode 
and a platinum wire auxiliary electrode as the anode. Recovery of
acrylamide in the polyacrylamides was reported to be greater than 90%. The 
detection limit for acrylamide was less than 1 jug/ml. However, the
presence of some nonionic species, substituted acrylamide, or acrylates 
would be electroactive in the same potential region as that of acrylamide 
and would thus interfere with polarographic acrylamide analysis. 
Acrylonitrile also interfered but, because of its high volatility, it was
purged readily by nitrogen from the solution with no adverse effects on
acrylamide concentration. Acrolein, acrylic acid, acetone, vinyl-benzyl
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chloride, vinyl-benzyl alcohol, styrene, and beta-hydroxypropionitrile did 
not interfere in polarographic analysis of acrylamide. Resin treatment of 
the methanolic extract of polyacrylamide for 20 minutes removed the ionic 
species, such as sodium and potassium ions, without causing any detectable 
loss of acrylamide concentration.
The analysis of monomeric acrylamide by differential pulse 
polarography has been adapted for determining airborne acrylamide [58]. 
The sampling solution for dust and vapor from impingers was analyzed for 
acrylamide polarographically after ion-exchange resin treatment and the 
addition of the supporting electrolyte tetra-n-butylammonium hydroxide. No 
information on the accuracy or the precision for this analytical method was 
provided. The method was claimed to be reasonably specific for acrylamide 
and to have relatively few interferences. It was also reported that an 
acrylamide concentration as low as 0.5 jug/ml could be determined by 
analysis.
A major factor for identifying the most appropriate analytical 
technique for acrylamide is the sensitivity of the instrumentation. It 
appears that gas-chromatographic analysis [60,63] of acrylamide in a 
methanol-water extract and of 1,2-dibromoproprionamide (derivative of 
\ acrylamide) yields sensitivities of 0.400 pg/ml [63] and a working
concentration range of 0.005-0.160 mg/cu m [60]. The sensitivity for 
differential pulse polarography was less than 1 /¿g/ml for the detection and 
determination of acrylamide in polyacrylamides [67]. The differential 
pulse polarography adopted for determining airborne acrylamide dust and 
vapor concentrations has a reported sensitivity of 0.5 Mg/ml of impinger 
solution [58]. Since both the polarographic and chromatographic analyses
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have sensitivities in the microgram range, these analytical methods are 
applicable to measure acrylamide air concentrations down to 0.15 mg/cu m of 
acrylamide. However, the gas-chromatographic method involves a complex 
number of steps for derivative formation and sample preparation, therefore 
reducing reliability and reproducibility. The efficiencies of bromination 
and subsequent irradiation are also unknown. Therefore, differential pulse 
polarography is recommended as the method of choice for the determination 
of acrylamide.
Environmental Levels
No published information has been found on atmospheric concentrations 
of acrylamide in industry. Two companies have supplied NIOSH with the
results of air sampling data taken at their plants.
Clyne (written communication, July 1976) reported on sampling 
performed in the breathing zone of workers who wore respirators and were
exposed in the acrylamide operation. The results of the 4-hour samples for 
two packers, the reactor operator, and the dryer operator were 0.22 ppm
(0.76 mg/cu m), 0.15 ppm (0.52 mg/cu m), 0.14 ppm (0.48 mg/cu m), and 0.15
ppm (0.52 mg/cu m), respectively.
The Vistron Corporation (DR Brinkley, written communication, June 
1976) supplied information on stationary sampling sites of an acrylamide 
manufacturing plant. Eight-hour samples were collected in water containing 
impingers and analyzed by a colorimetric method using a ferric chloride 
reagent. The sampling was begun in January 1971 for the control room and 
bagging room and in June 1974 for the second-floor processing area. The 
sampling continued until May 1975. The data were presented as weekly
76
averages and ranged from 0.1 to 0.4 mg/cu m for the control room, 0.1 to 
0.9 mg/cu m for the bagging room, and 0.1 to 0.4 mg/cu m for the second- 
floor processing area. The stationary air monitoring was reported not to 
be representative of worker exposure and, therefore, exposure 
concentrations were estimated from the time each employee worked in the 
three areas where stationary air monitoring was done. These calculated 
concentrations usually did not exceed 0.3 mg/cu m during normal operation.
Limited personal monitoring was performed in one plant from late 1974 
until June 1975. Two methods were used for collecting acrylamide samples, 
ie, an 0.8-/im cellulose acetate membrane filter and sodium carbonate. No 
other specific information was given. The limited personal monitoring data 
indicated that the actual exposure concentrations were two to three times 
higher than those of the stationary sites. Table XII-3 shows these data.
Engineering Controls
In the industrial manufacturing of monomeric acrylamide and in the 
production of its polymers and copolymers, both the solid and aqueous forms 
of acrylamide are encountered [1,68], the solid having a vapor pressure of 
0.007 mmHg at 25 C [1]. The saturated vapor concentration in air for solid 
acrylamide monomer under standard conditions is estimated to be 27 mg/cu m. 
During industrial operations in which acrylamide is used for 
polymerization, both vapor and particulate forms of acrylamide are, and 
should be, monitored [57 (pp 47-48)]. Concentrations and relative 
percentage data are not available. The control of exposure to acrylamide 
should therefore emphasize engineering designs which prevent the escape of
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both vapor and dust into the environment.
Any line system or storage vessel necessary for the transfer, 
maintenance, or manufacture of solid or aqueous acrylamide should be 
enclosed, ventilated, and have other engineering controls, preferably 
automated systems, to provide a healthful work environment to minimize 
worker exposure to acrylamide [57 (pp 133-36)]. In the handling of aqueous 
acrylamide, skin and eye contact must be prevented. A closed system may be 
the best way to accomplished this. The liquid should be transferred in a 
closed-line system from the storage vessel to the polymerization reactor 
[57 (p 133)]. Closed systems that are properly designed, operated, and 
maintained should be used, where practical, for the containment of vapor 
and dust from acrylamide. The conventional method of filling storage tanks 
or reactor vessels manually with the solid or aqueous acrylamide monomer 
should be replaced with an automated, enclosed, or ventilated system [57 
(pp 133-36)]. Strict engineering controls should minimize skin contact and 
inhalation hazards associated with acrylamide exposure.
If closed systems are not feasible, local exhaust ventilation should 
be provided. Guidance for proper design can be obtained in Industrial 
Ventilation— A Manual of Recommended Practice [69] , or more recent 
revisions, and in ANSI Z9.2-1971 [70], All ventilation air that contains 
acrylamide vapor or dust or has contacted solid acrylamide shall be 
controlled to meet with EPA and local air standards; exhaust air shall not 
be recirculated into the workplace [57 (p 59)].
Engineering controls should be complimented with good work practices 
for more effective control of exposure to acrylamide. Respiratory
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protective equipment should not be used as a substitute for proper 
engineering controls but must be worn when the worker is exposed to dust or 
vapor concentrations exceeding the environmental exposure limit.
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V. DEVELOPMENT OF A STANDARD
Basis for Previous Standards
The acrylamide environmental limit was first introduced in 1966 in 
the United States by the American Conference of Governmental Industrial 
Hygienists (ACGIH) as a tentative Threshold Limit Value (TLV) of 0.3 mg of 
acrylamide/cu m of air with the notation "Skin" [71]. This designation is 
intended to suggest the need for appropriate measures for the prevention of 
dermal or other local contact or absorption. The tentative TLV of 0.3 
mg/cu m was adopted as the recommended value by the ACGIH the following 
year [72] , and has remained unchanged since 1967 [73].
According to the 1971 (third) edition of Documentation of the 
Threshold Limit Values for Substances In Workroom Air [74], the basis for 
the ACGIH TLV was extrapolation from long-term feeding experiments on cats 
reported by McCollister et al [34] in 1964. The oral LD50 for laboratory 
animals (rats, guinea pigs, and rabbits) was in the range of 150-180 mg/kg 
and the document [74] further stated that "toxic effects may be produced by 
any route of administration— ingestion, inhalation, injection, skin 
contact, or contact with the eye." The cat was described in this document 
as the most sensitive species. Cats given acrylamide at a dose of 1 
mg/kg/day by iv or ip injection developed the neurologic effects in about 6 
months; however, long-term feeding experiments (0.3 and 1 mg/kg/day, 5 
days/week, for 1 year) in this same species apparently did not produce any 
ill effect. From the results of long-term feeding experiments in the most 
sensitive species, the cat, the ACGIH recommended "that no more than 0.05
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mg/kg/day be absorbed by workmen" [74].
According to this 1971 ACGIH Documentation of TLV's [74], an 
absorption of 0.05 mg/kg/day, assuming a ventilation rate of 10 cu m of air 
for each 8-hour workday, corresponds to an environmental limit of 0.3 
mg/cu m, or about 0.1 ppm. The present federal standard for acrylamide, 
0.3 mg/cu m as a TWA concentration with the notation "Skin" (29 CFR 
1910.1000), is based on the 1968 ACGIH Threshold Limit Value.
According to a 1968 joint report of the International Labour Office 
and the World Health Organization [75] , no standards for acrylamide had 
been promulgated by countries other than the United States.
Basis for the Recommended Standard
The studies of human intoxication with acrylamide have indicated that 
dermal absorption [16-18,20,21,23] and ingestion [22] have been the main 
routes of exposure without, however, ruling out the possible contribution 
of inhalation of aerosol or vapor. In addition, the airborne form of 
acrylamide (vapor or aerosol) has not been positively identified. Little 
information has been found on the acrylamide concentrations to which people 
are occupationally exposed [16-21,23], much less the airborne 
concentrations of acrylamide that have caused adverse effects (DR Brinkley, 
written communication, June 1976). However, data obtained from Vistron 
Corporation (DR Brinkley, written communication, June 1976) showed that 
airborne concentrations of acrylamide ranged from 0.1 to 3.6 mg/cu m for 
personal monitoring and from 0.1 to 0.3 mg/cu m for stationary sites at an 
acrylamide manufacturing plant. No information was presented in this 
report to correlate personal monitoring data with the incidence of skin
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peeling. The author indicated that a correlation existed between skin 
reactions and airborne acrylamide concentrations obtained from stationary 
site data in the plant. In addition to these airborne concentrations of 
acrylamide, Brinkley stated that two employees experienced neurologic 
symptoms and initial symptoms of erythema and skin peeling were noted in 
almost every employee who was working in the acrylamide plant.
Garland and Patterson [20] reported six human cases of occupational 
acrylamide intoxication. The duration of exposure before the onset of 
symptoms varied from 4 weeks to 13 months. Though no solid or aqueous 
acrylamide concentrations to which people were dermally exposed was
reported, most of the patients showed excessive sweating, weakness, and 
skin peeling as initial signs of toxicity. In another occupational dermal 
exposure study, Auld and Bedwell [16] described a 21-year-old worker who 
came into contact with a 10% aqueous solution of acrylamide. The patient 
showed hand and leg muscle weakness as the first symptom of acrylamide
intoxication. The authors [16] reported that another worker stopped work
because of tiredness and skin rashes. After 2 weeks, he was able to return 
to work with no complaints. The other occupational incidents of monomeric 
acrylamide intoxication were reported by Cavigneaux and Cabasson [18],
Graveleau et al [17], and Morviller [19] in France and by Fujita et al [23] 
and Takahashi et al [21] in Japan. However, all of these reports on human 
effects are qualitative and deal only with clinical signs and symptoms of 
acrylamide intoxication.
Igisu et al [22] described a nonoccupational exposure to monomeric 
acrylamide in a family of five persons who used acrylamide contaminated 
well water for cooking, drinking, washing, and bathing. Three adults in
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the family showed signs of CNS toxicity manifested by ataxia. This was 
followed in 2-4 weeks by symptoms of peripheral neuropathy. The well water 
was analyzed by gas chromatography and shown to contain 400 ppm of 
acrylamide and a trace of dimethylaminoproprionitrile. Although slightly 
more quantitative information was presented in this report than in the 
reports on occupational exposures [16-21,23], no information is available 
which would allow estimation of dermal or airborne exposure limits from 
this report.
There is abundant documentation that experimental administration of 
acrylamide has produced peripheral neuropathy in many animal species: hens
[56], rats [27,38,39], mice [33], cats [34-36,41], dogs [14,30], baboons 
[31,32], and monkeys [34]. There is some evidence that acrylamide, at a 
higher dose than that necessary to produce peripheral neuropathy, has 
caused damage to the CNS of a baboon [32]. Hamblin [14] reported that 
neurotoxic effects of acrylamide were dose dependent and cumulative, 
similarly Kuperman [41] found that the CNS effects of acrylamide depended 
on the dose magnitude, rate of administration, and the length of time 
during which it was administered in cats. The author [41] did not find any 
differences in the chronic effects of acrylamide when given by different 
routes. Kuperman [41] stated that whether the route was iv, ip, im, oral, 
or subcutaneous, the characteristic effects of chronic poisoning appeared 
at identical dose levels and after equivalent latencies.
Hashimoto and Ando [37] and McCollister et al [34] have described 
studies in which acrylamide was applied dermally. Hashimoto and Ando [37] 
demonstrated the dermal penetration of a 10-30% solution of acrylamide 
which subsequently appeared in the blood. In rabbits, application of
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aqueous solutions of acrylamide (10 and 12.5%) killed one of two rabbits at 
a dose of 1 g/kg and resulted in slight toxicity at 0.5 g/kg [34]. 
McCollr'ster et al [34] also studied the effects of 10 and 40% aqueous 
solutions of acrylamide instilled into the eyes of rabbits. The 10% 
aqueous solution caused signs of slight pain and slight conjuctival 
irritation, while the 40% aqueous solution caused moderate pain, slight 
conjunctival irritation, and marked corneal injury.
McCollister et al [34] found that acrylamide in the feed at 0.3 
mg/kg/day, 5 days/week, for 1 year produced no adverse effect on cats. 
A dose of 1 mg/kg/day caused questionable effects, whereas the higher doses 
of 3 and 10 mg/kg/day resulted in definite signs of neurotoxicity. The 
authors [34] found that one monkey fed with 0.1 mg/kg/day, two with 0.3 
mg/kg/day, and one with 1 mg/kg/day, 5 days/week, for one year also showed 
no adverse effects. However, 3 and 10 mg/kg/day levels did cause signs of 
neurotoxicity in monkeys. The authors [34] concluded that the "no adverse 
effect" level for monkeys on a diet containing acrylamide lay between 1 and 
3 mg/kg/day. It was the authors' [34] suggestion that the summation of 
industrial exposures should be so controlled that it will be almost 
impossible for a worker to absorb more than 0.05 mg/kg/day of acrylamide on 
a day-to-day basis. As previously stated, studies of human intoxication 
with acrylamide have indicated that dermal contact and ingestion may have 
been the main routes of exposure without neglecting the possible 
contribution of inhalation of aerosol or vapor. Consequently, without 
knowing the airborne acrylamide concentrations at which skin and neurologic 
symptoms manifest themselves, and also in the absence of information as to 
the primary routes of exposure, ie, dermal, inhalation, or ingestion, by
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which these symptoms may be produced, it is difficult to correlate dermal 
or neurologic symptoms with worker exposure to airborne acrylamide. The 
available human and animal studies do not provide enough information to 
alter the existing federal standard for acrylamide of 0.3 mg/cu m of air as 
a TWA value. NIOSH, therefore, recommends that the present federal 
standard be kept.
Several human [16-18,20,21,23] and animal [34,37] studies reported 
that dermal exposure of monomeric acrylamide produced skin peeling, eye
irritation, and signs of neurotoxicity. Thus, a medical surveillance 
program should include preplacement and periodic medical examinations that 
give attention to nervous system, skin, and eyes. Medical attention should 
be provided to workers accidentally overexposed to acrylamide. Personnel 
occupationally exposed to acrylamide must be warned and advised of the 
adverse effects of accidental overexposure and must be informed of the 
symptoms of the disorders and that they may be delayed in onset. If eye 
contact occurs, the affected eye should be immediately flushed with water 
and examined by a physician. Each worker's fingers should be examined by 
medical, paramedical, or other properly trained personnel. Workers should 
be informed of the importance of this examination.
A continuing education program is an important fact of a preventive
hygiene program for employees exposed to hazardous materials such as
acrylamide. Workers should be periodically apprised by properly trained 
persons about the possible sources of acrylamide exposure, the adverse 
health effects associated with excessive exposure to acrylamide, the
engineering and work practice controls in use and being planned to limit 
exposure to acceptable concentrations, and on environmental and medical
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monitoring procedures used to check on control procedures and on the health 
status of employees. The types and functions of monitoring equipment, such 
as personal samplers, should be explained so that each employee understands 
his or her part in environmental monitoring.
Because dermal contact by acrylamide induced skin irritation and 
neuropathy in humans and animals, care must be exercised to ensure adequate 
protection against contact with acrylamide. Personal protective clothing 
and respiratory protective equipment should be available and worn where 
indicated. Work practices that prevent skin and eye contact must be 
followed. Showers and eyewash fountains must be available for immediate 
use if accidental contact occurs.
Engineering controls must be used whenever feasible to control 
airborne concentrations of acrylamide monomer within the recommended TWA 
limit. Where acrylamide monomer is present, a closed system of control 
should be used. During the time required to install adequate controls and 
equipments, to make process changes, to perform routine maintenance and 
operations, or to make repairs, overexposure to acrylamide can be prevented 
by the use of respirators and protective clothing and in some cases by 
administrative controls.
Because acrylamide produces delayed neuropathy, it is recommended 
that all medical and other pertinent records involving acrylamide exposure 
be maintained for 20 years after termination of employment. This will 
allow enough time for future detection of chronic neurotoxicity of 
acrylamide which may be related to the employee's known occupational 
exposure.
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The technology is currently available to sample and analyze the 
present environmental limit to institute appropriate engineering controls. 
As was discussed in greater detail in Chapter IV, a midget impinger is 
recommended for personal breathing zone sampling of airborne acrylamide 
aerosol and vapor to guard against losses attendant with filter sampling. 
Current analytical techniques commonly used for the determination of 
acrylamide in the industrial environment are differential pulse 
polarography and gas chromatography. As was discussed in Chapter IV, 
differential pulse polarography is the analytical method of choice for 
airborne acrylamide since gas chromatography involves complex derivative 
formations of unknown efficiencies and sample preparation.
Concern for worker health requires that protective measures be 
instituted below the enforceable limit to ensure that exposures stay below 
that limit. An action level is set as a TWA concentration of one-half the 
environmental limit. It has been chosen on the basis of professional 
judgment rather than on quantitative data that delineate nonhazardous areas 
from areas in which a hazard may exist. However, in the case of acrylamide 
it is also recognized that many employees work with solid or liquid forms 
of the substance in situations where there may be skin contact with the 
substance resulting in dermal or systemic effects. Consequently, 
appropriate work practices, training, and other protective measures should 
be required regardless of concentrations of acrylamide in air. Therefore, 
occupational exposure to acrylamide has been defined as work in an area 
where acrylamide is stored, produced, processed, or otherwise used, except 
as an unidentified contaminant in other material at a concentration of less 
than 1% by weight. Under these conditions, all provisions of this
recommended standard except environmental monitoring and associated 
recordkeeping should be complied with; in work areas where the action level 
is exceeded, this requirement (Section 8) should also be complied with.
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VI. WORK PRACTICES
Occupational exposures can occur in the manufacture of solid forms of 
acrylamide [19,23], in the preparation and utilization of aqueous solutions 
of acrylamide [16], in the polymerization process [20], and in the handling 
of polymerized products which contain the residual monomer [17,18].
The conventional way of cutting bags of solid monomeric acrylamide 
manually with a knife and dumping the pellets or flakes into the reactor 
for polymerization should be replaced with a method that limits exposure to 
acrylamide. One method that has been used is a mechanized, maximally 
enclosed, or ventilated system [57 (p 135)]. The only manual step in this 
process involves placing the bags on the cutter; the rest is handled 
mechanically. The bags are cut open automatically and the solid acrylamide 
is dropped by gravity into the hopper of a bin. Any dust or vapor may be 
controlled by a canopy-type local exhaust ventilation and trapped by a 
filter. The empty acrylamide bags are transferred on a moving conveyor to 
a compressor, where they are compacted and automatically inserted into 
plastic bags for disposal. There is less chance of acrylamide escaping in 
this system if the hopper is connected directly to the reactor.
The trend of some manufacturers to replace solid crystalline forms 
with aqueous solutions of monomeric acrylamide has warranted special work 
practices in handling the liquid form. Because of the high dermal hazard 
of the aqueous solution of acrylamide, liquid acrylamide should be 
transferred from the truck to the storage tank and from the tank to the 
reactor in closed-line systems [57 (pp 134-35)]. If pressure buildup is a 
problem, then the tank should be equipped with an alarm system to signal
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any internal pressure buildup so that corrective measures or evacuation of
the area may be accomplished as needed [57 (p 135)]. Filters installed on
top of the storage tanks should be routinely checked and replaced as
necessary. Safety features on the tanks should also be checked regularly
and corrected when found defective. Precautions should be taken for line 
opening and tank entry [57 (pp 58-59) ,76] . Before opening up a line, the 
worker or workers should set up a barricade to isolate the area and check 
the condition and location of the nearest eyewash fountain and safety 
shower. All workers involved in this operation must be supplied with whole 
body protection, including air-supplied respirators (self-contained or 
airline). This protective equipment should be worn when entering the tank 
unless it is known that entry into the tank is safe. A second properly 
protected worker must be on standby outside the tank [76],
In addition to sound engineering controls, work practices should 
emphasize personal protective devices, good housekeeping, and personal 
hygiene. To minimize dermal contact with solid or liquid acrylamide, all 
workers and nonworkers entering work areas should wear protective clothing 
including long-sleeved coveralls, head covering including face shield 
(8-inch minimum), protective footwear, and impervious gloves or neoprene 
gloves with cotton liners [57 (p 6)]. Soiled protective clothing provided 
at the beginning of each work shift should be left in bins at the workplace 
for laundering after work. Protective and personal clothing should be kept 
in separate lockers [76].
If there is any chance of skin contact with acrylamide, then the 
protective clothing worn should be impervious to acrylamide. At the 
present time, the suitability of impervious clothing for the protection of
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the worker has not been adequately established. In addition, it is 
difficult for workers to wear this clothing for extended periods of time. 
These factors emphasize the need for showers, eyewash fountains, and proper 
engineering controls.
Protective clothing and some polyvinyl chloride (PVC) coated gloves 
have shown a wide variation of permeability to acrylamide [77]. Of the 
different types of gloves tested for resistance to penetration in an 8-hour 
test period from a 50% acrylamide solution, the Edmond Snorkel Vinyl-coated 
glove has been reported to have low permeability to acrylamide, whereas 
PVC-coated gloves have proven to be more permeable to acrylamide. 
Therefore, to ensure employee protection against dermal acrylamide 
exposure, all protective clothing and glove types should be first tested
for their permeability to acrylamide before being worn. For further dermal
protection against acrylamide, all protective clothing should have a cotton 
lining for comfort.
Impervious gloves with separate cotton liners and impervious long- 
sleeve overalls must be worn when handling equipment or containers used in 
acrylamide operations. The gloves should be either gauntlet type or long 
enough to overlap the sleeve [57 (pp 48-51),78]. A supply of these gloves
should be on hand in the workplace. After work, the outside of the gloves
must be washed before removal from the hands; if contaminated on the 
inside, hands must be washed immediately and the gloves should be replaced 
by a clean pair. Since eye irritation has been reported in acrylamide 
operations [1] and acrylamide is volatile [1,3,4], chemical safety goggles 
[76] should be worn in operation areas. Face shields are required in 
addition to chemical safety goggles during line openings involving liquid
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acrylamide [76]. Eyewash fountains and emergency showers also should be 
available in acrylamide work areas [57 (p 6)]. It has been reported [3] 
that acrylamide monomer is neither an explosion nor a fire hazard when 
stored at room temperature.
Solid acrylamide wastes, including compressed contaminated bags, 
drums, drum liners, or containers should be disposed of either by burial in
an approved landfill away from drinking water sources or by burning in an
approved industrial incinerator [76] . Decontaminated liquids or any 
aqueous acrylamide waste solutions should be drained to a sump for 
subsequent treatment by an approved facility.
Good housekeeping must be instituted to minimize the hazards of
acrylamide inhalation. Floors constructed of concrete in operation areas 
should be sealed with a layer of impervious material to prevent the
trapping of acrylamide that may otherwise occur and to facilitate the
removal of spills [57 (p 135)]. Certain types of epoxy resin floors are 
the most impervious to acrylamide penetration [77] . Thorough testing 
should be conducted to investigate varying degrees of acrylamide 
penetration through the epoxy resin floor covering before any epoxy resin 
or other material is used as an impervious floor covering. Coroline 505
(an epoxy resin) is said to have a high degree of resistance to acrylamide
penetration as a concrete floor covering. Other floor covering 
formulations may also be effective. When spilled, solid acrylamide should 
be either wet vacuumed or mopped up immediately and deposited in a covered 
drum [57 (p 135)]. One quart each of 1.6% potassium persulfate solution 
and 1.6% sodium metabisulfite solution should be mixed and used to
decompose each pound of acrylamide in the drum [57 (p 22)]. After 30
minutes, the contents of the drum should be properly disposed of. The 
residual acrylamide on the floor should be mopped with a mixture of 3 
gallons each of potassium persulfate and sodium metabisulfite for every 250 
square feet of floor area and the liquid residue should be properly 
disposed of. Any acrylamide spilled on the surface of equipment should be 
removed and transferred to a covered drum and treated as described for 
floor spills. Contaminated equipment surfaces should be washed with a 
mixture of potassium persulfate (1.6%) and sodium metabisulfite (1.6%) 
solution by a worker wearing impervious long-sleeve overalls and rubber 
gloves. The floor area adjacent to contaminated equipment should be 
treated with the mixed solution.
Good sanitation and personal hygiene practices should minimize the 
risk of acrylamide ingestion. Hands should be washed before drinking, 
eating, or smoking. Food and beverages consumption or smoking should not 
be allowed in any acrylamide work or storage areas. Showering is 
recommended after each work shift [57 (pp 6,46)] before leaving the 
workplace where acrylamide is handled.
For emergency conditions such as spills and leaks, full body 
protection, including an air-supplied respirator, must be worn [76]. If 
the eyes come into contact with acrylamide, they should be immediately 
flushed with low-pressure flowing water for at least 15 minutes. Any skin 
contacting acrylamide should be immediately washed with soap and flowing 
water. Vomiting should be induced if acrylamide is ingested and the worker 
is conscious. A physician should be contacted immediately. Employees, 
physicians, and other medical attendants should be informed of the 
possibility of delayed neurologic effects. All employees should be trained
and verbally informed about accident and first-aid procedures and use of 
respirators. They should also be informed of the hazardous areas, with 
special instruction given to illiterate employees.
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VII. RESEARCH NEEDS
Two routes of entry, dermal and inhalation, are of major concern in 
occupational exposure to acrylamide. Only two animal study reports have 
briefly described the absorption [37] and toxicity [34] aspects of 
acrylamide after dermal applications. No inhalation studies on humans or 
animals have been found to date. The toxicity in animals of acrylamide 
administered by dermal and inhalation routes should be investigated as this 
chemical exists as an aerosol or vapor in the industrial work environment. 
Such studies should involve investigation of both short- and long-term 
effects.
No epidemiologic report on acrylamide has been found in the 
literature to date. Such studies are needed to provide information on 
occupational exposures to acrylamide and to determine the relationship 
between airborne concentrations and observed effects on humans. No human 
or animal studies have been found in the literature regarding the 
possibility of carcinogenic, mutagenic, or teratogenic or other 
reproductive effects of acrylamide. However, Hashimoto and Aldridge [38] 
have observed a low level of incorporation of iv-administered 14C- 
acrylamide in the DNA and RNA of rat brain and liver. These observations 
and the fact that acrylamide bears a structural resemblance to other 
biologically active compounds, including a known carcinogen, vinyl 
chloride, would suggest that acrylamide may produce mutagenic or 
carcinogenic effects in mammaliam systems. However, there is insufficient 
information to draw any conclusion at this time. Research efforts should 
be initiated in these areas to answer these important questions. Studies
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are now being conducted by NIOSH to investigate any mutagenic potential of 
acrylamide.
Although the effects of acrylamide on the CNS are suggested by the 
results of human [21,22] and animal [39,42,52] studies, the extent and 
reversibility of the changes after short-term exposure, and the structural 
damage after prolonged, low concentration exposure are not clear at this 
time. Further research is therefore indicated in this area. Except in a 
few studies [34,47,55], acrylamide has been used by various workers as a 
tool for investigating its mechanism of action in causing peripheral 
neuropathy in experimental animals. Toxicologic information on other 
physiologic systems (such as cardiovascular, renal, hepatic, and pulmonary) 
is lacking. Detailed investigations of the effects of acrylamide on these 
organ systems in animals need to be done.
Available information on the pharmacokinetics of acrylamide is 
inadequate. It is not known whether the toxicity of acrylamide is from the 
parent compound or its metabolite or metabolites. The half-life of 
acrylamide in the blood, plasma, and in various tissues along with fecal 
and urinary excretion rates should be investigated. Interdisciplinary 
studies are needed to determine the metabolic/biochemical basis for 
neurotoxicity and why the distal parts of central and peripheral nerve 
fibers are most vulnerable to systemic acrylamide intoxication.
At present, no sensitive tests are available for early diagnosis of 
adverse effects to acrylamide. There is a need to develop a sensitive, 
practical, and economical test for this purpose. Research efforts are in 
progress to develop such a test at Albert Einstein College of Medicine of 
Yeshiva University.
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Tomcufcik et al [10] found that various acrylamide compounds 
inhibited the growth of tumors in mice. Ismaylova [11] also found the same 
inhibition property in tomato plant tumors and Ismaylova et al [12] in 
plant tissue cultures. This property might be interesting to investigate 
in mammals.
The recommended impinger sampling method for acrylamide has several 
disadvantages when used for personal monitoring. These include breakage of 
the glass impinger and spillage of the absorption solution during sampling 
and subsequent shipment to the laboratory unless extreme care is taken. A 
method of personal monitoring using a membrane filter followed by a silica 
gel tube or other adsorbent tubes should be evaluated. The efficiency of 
the method sought should apply equally to the collection of both acrylamide 
dusts and vapors. Differential pulse polarography and gas chromatography 
are the commonly used analytical techniques for the determination of 
acrylamide in the industrial environment. Differential pulse polarography 
requires validation of its reliability and reproducibility while gas 
chromatography needs the development of an improved derivatization 
technique.
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IX. APPENDIX I
The recommended sampling method presented is a modification of that 
described in the Dow Chemical Company analytical method PAA No. 46 [58].
Collect breathing zone samples representative of the individual 
employee's exposure. Collect enough samples to permit calculation of a 
time-weighted average (TWA) concentration for every operation or location 
in which there is exposure to acrylamide. At the time of sample 
collection, record a description of sampling location and conditions, 
equipment used, time and rate of sampling, and any other pertinent 
information.
The midget impinger recommended must be operated in a uniform and 
consistent way if data obtained are to have meaning in the assessment of 
environmental conditions. The impinger should be made of glass in all 
portions that may contact the collection medium or the airstream before 
collection is effected. It should be emphasized that the distilled water 
used as a collection medium must be free of contaminating substances that 
produce interferences (see Appendix II) when analyzed by polarography.
Equipment
The sampling train consists of a sampling pump and an all-glass 
midget impinger filled with 10 ml of distilled water. The sampling pump is 
protected from splash-over or water condensation by an adsorption tube 
loosely packed with a plug of glasswool and inserted between the exit arm
METHOD FOR SAMPLING ACRYLAMIDE IN AIR
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of the impinger and pump or, preferably, by a water trap inserted in the 
same location.
Calibration
Since the accuracy of environmental monitoring can be no greater than 
the accuracy of the air volume measurement, the accurate calibration of a 
sampling pump is essential to the correct interpretation of the volume 
indicated. The frequency of calibration is dependent on the use, care, and 
handling to which the pump is subjected. Pumps should also be recalibrated 
if they have been misused or if they have just been repaired or received 
from a manufacturer. If the pump receives hard usage, more frequent 
calibration may be necessary. Regardless of use, maintenance and 
calibration should be performed on a regular schedule and records of these 
should be kept.
Ordinarily, pumps should be calibrated in the laboratory. The 
accuracy of calibration is dependent on the type of instrument used as a 
reference. The choice of calibration instrument will depend largely upon 
where the calibration is to be performed. For laboratory testing, primary 
standards, such as a spirometer or a soapbubble meter, are recommended, 
although other standard calibration instruments, such as a wet-test meter 
or dry gas meter, can be used. The actual setups will be similar for all 
instruments.
Instructions for calibration with the soapbubble meter follow. If 
another calibration device is selected, equivalent procedures should be 
used. Since the flowrate given by a pump is dependent on the pressure drop 
of the sampling device, in this case an impinger, the pump must be
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calibrated while operating with a representative filled impinger in line. 
The calibration system should be assembled in series following this order: 
soapbubble meter, water manometer, midget impinger, and pump as shown in 
Figure XII-1.
(a) Check the voltage of the pump battery with a voltmeter to 
ensure adequate voltage for calibration and charge the battery if 
necessary.
(b) Turn on the pump and moisten the inside of the soapbubble 
meter by immersing the buret in the soap solution and drawing bubbles up 
the inside until they travel the entire buret length without bursting.
(c) Adjust the pump rotameter to provide the desired flowrate.
(d) Check the water manometer to ensure that the pressure drop 
across the sampling train does not exceed 13 inches of water at 1 
liter/minute.
(e) Start a soapbubble up the buret and measure with a stopwatch 
the time required for it to move between calibration marks.
(f) Repeat the procedure in (e) above at least twice, average the 
results, and calculate the flowrate from the volume between the preselected 
marks divided by the time required for the soapbubble to traverse the 
distance.
(g) Record the volume measured, elapsed time, pressure drop, air 
temperature, atmospheric pressure, serial number of the pump, the date, 
time, and name of the person performing the calibration.
(h) The rotometer reading should be corrected for temperature and 
pressure, if necessary.
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Sampling Procedure
Any air mover capable of drawing the desired flowrates through the 
impinger may be used, so long as flowrates do not vary more than ± 5%
during the sampling period. The sampling pump must be capable of operating 
at a pressure drop of 13 inches of water while providing a flow of 1 
liter/minute.
(a) For samples representative of an individual employee's
exposure, place the midget impinger within the breathing zone of the 
exposed employee by inserting it into a holster for fastening to the 
employee's coat lapel or shirt collar, or hold the impinger near the face 
of the employee during the sampling period.
(b) Collect an air sample at a flowrate of 1 liter/minute. The
flowrate of the pump must be calibrated and this calibration checked
periodically to ensure that it has not changed.
(c) Transfer the contents of the impinger to a sample bottle for
shipping. Wash the impinger, stem, and splash-over with 2-5 ml of
distilled water, add the washing solution to the sample bottle, and record
the exact amount of distilled water used. Seal the sample bottle tightly 
and place it upright in a carrying case. Every attempt should be made to 
prevent losses from spillage or evaporation.
The trapped acrylamide is analyzed as described in Appendix II. 
Other collection methods shown to be equivalent may be used.
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X. APPENDIX II
The following analytical method for acrylamide is adapted from those 
described by Betso and McLean [67] and presented in the Dow Chemical 
Company analytical method PAA No. 46 [58].
Scope
This method is applicable to the determination of acrylamide monomer 
which may be present in the air in an industrial environment. The 
procedure is described for measuring potential employee exposure. Amounts 
of 5-200 Mg of acrylamide/10 ml of aqueous solution can be determined; 
larger amounts of acrylamide may be determined by appropriate dilution 
[58].
Principle of the Method
A known volume of air is drawn through a midget impinger filled with 
distilled water to collect the acrylamide dust and vapor. Two ml of sample 
are mixed with 8 ml of methanol. An aliquot of the sample is treated with 
ion-exchange resin and a fraction is injected into a differential pulse 
polarograph. The response of the resulting peak is determined and compared 
with responses obtained from the addition of standards. Polarographic 
response is based on the electrochemical reduction of the acrylamide double 
bond.
ANALYTICAL METHOD FOR ACRYLAMIDE
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Range and Sensitivity
The polarographic detection limit for acrylamide in a clean system is 
less than 1 pg of acrylamide/ml of acrylamide solution [67], Even at this 
low concentration, the acrylamide reduction peak is well-defined and 
resolved from the background.
Interferences
Differential pulse polarography is reasonably specific and relatively 
free from interferences. In addition, the ion-exchange resin treatment 
removes most common interferences, such as acrylic acid, acrylonitrile, and 
sodium and potassium ions. However, any compounds which are reducible in 
the same potential region (-2.0 v) will interfere. Substituted acrylamides 
and acrylate esters are reducible in the same potential region and, if 
present, will interfere.
Apparatus
(a) Glass-fiber filter disc, or equivalent.
(b) Magnetic stirrer and bar.
(c) Differential pulse polarographic analyzer (Princeton Applied
Research (PARC) Model 174 equipped with PARC droptimer or equivalent).
(d) Two dimensional (x-y) recorder, or equivalent.
(e) Polarographic cell, 10-ml, equipped with a dropping mercury
working electrode, a platinum-wire counterelectrode, and a saturated 
calomel reference electrode connected to the cell via a tetra-n- 
butylammonium chloride bridge. The cell should be equipped for deaeration 
with solvent-saturated, oxygen-free nitrogen.
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(f) A gas scrubbing tower filled with a methanol-water solution 
(80:20 V/V) for nitrogen scrubbing.
(g) Eppendorf pipet, 100-/il, or equivalent.
(h) Watch glass.
(i) Beakers, 10- and 20-ml.
(j) Volumetric flasks, 100- and 250-ml.
Reagents
(a) Methanol, ACS reagent grade.
(b) Methanol-water solution (80:20 V/V).
(c) Nitrogen, oxygen-free (prepurified).
(d) Mixed ion-exchange resin, Bio-Rad Analytical Grade Mixed Bed 
Resin Ag 501-X8 or equivalent.
(e) Tetra-n-butylammonium chloride, 1.0 M, polarographic grade.
(f) Tetra-n-butylatranonium hydroxide, 1.0 M, polarographic grade.
(g) Acrylamide, purified.
(h) Acrylamide standard solution. Accurately weigh about 0.02 g
of acrylamide, transfer it to a 100-ml volumetric flask, and dilute to 
volume with 80:20 methanol-water solution. The solution will contain 
approximately 200 fig of acrylamide/ml.
Preparation of Mixed Ion-Exchange Resin
Preextract and partially dry a 1-2 week supply as follows: fill a
16-oz bottle about half full of resin. Add about 200 ml of methanol and 
shake the tightly closed bottle for 8-24 hours. Decant the solvent through 
a suction filter and wash the resin twice (by décantation from the bottle)
110
using the methanol-water solution (80:20). Transfer the resin to the 
filter and wash twice more with the 80:20 solution. Air dry until the 
resin will fall off a tilted spatula. This washing procedure will give a 
resin which has an equal mixture of hydrogen and hydroxide ions.
Analytical Procedure
(a) Measure the volume of each sample to the nearest 0.1 ml.
Record the volume as "V."
(b) Add methanol: four times the volume measured in (a).
(c) Place 15 ml of the solution in (b) into a 20-ml beaker and add 
1 g of prepared resin and a miniature magnetic stirring bar. Cover the 
beaker with a watch glass, place on a magnetic stirrer, and stir for 20 
minutes.
(d) Prepare a reagent blank as in (c) using 15 ml of methanol- 
water solution in place of the sample solution.
(e) Transfer 10 ml of the resin-treated extract of the reagent
blank to the polarographic cell and add 0.5 ml of 1.0 M tetra-n- 
butylammonium hydroxide.
(f) Insert the electrodes into the cell and deaerate for 5 minutes 
by purging with nitrogen.
(g) Record the differential pulse polarogram from -1.6 to -2.4 v
against the saturated calomel electrode and a full-scale current range 
of 2 /aamp, a pulse height of 50 mv, and a drop time of 0.5 seconds.
(h) Repeat (e-g) employing 10 ml of the resin-treated sample.
I l l
(i) To the sample, add 0.1 ml of acrylamide standard solution
(20 jug) with a 100-jul Eppendorf pipet to each of the samples and repeat (f) 
and (g). Record micrograms of acrylamide added.
(j) Measure the peak height of the sample at about -2.0 v,
correcting for any blank reading, both before (value "A") and after (value
"B") adding acrylamide (i).
Calculations
Let F = micrograms of acrylamide added 
B-A
The total micrograms of acrylamide in the sample of air are calculated by
the following equation:
micrograms of acrylamide in the sample = 5 x (A) x (F) x (V)
10
= 0.5 x (A) x (F) x (V)
The concentration of acrylamide in the air sampled can be expressed in
mg/cu m:
mg/cu m = total micrograms of acrylamide in sample 
total volume of air sampled in liters
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XI. APPENDIX III 
MATERIAL SAFETY DATA SHEET
The following items of information which are applicable to a specific 
product or material shall be provided in the appropriate block of the 
Material Safety Data Sheet (MSDS).
The product designation is inserted in the block in the upper left 
corner of the first page to facilitate filing and retrieval. Print in 
upper case letters as large as possible. It should be printed to read
upright with the sheet turned sideways. The product designation is that 
name or code designation which appears on the label, or by which the
product is sold or known by employees. The relative numerical hazard 
ratings and key statements are those determined by the rules in Chapter V, 
Part B, of the NIOSH publication, An Identification System for
Occupationally Hazardous Materials. The company identification may be
printed in the upper right corner if desired.
(a) Section I. Product Identification
The manufacturer's name, address, and regular and emergency telephone 
numbers (including area code) are inserted in the appropriate blocks of
Section I. The company listed should be a source of detailed backup
information on the hazards of the material(s) covered by the MSDS. The
listing of suppliers or wholesale distributors is discouraged. The trade 
name should be the product designation or common name associated with the 
material. The synonyms are those commonly used for the product, especially 
formal chemical nomenclature. Every known chemical designation or
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competitor's trade name need not be listed.
(b) Section II. Hazardous Ingredients
The "materials" listed in Section II shall be those substances which 
are part of the hazardous product covered by the MSDS and individually meet 
any of the criteria defining a hazardous material. Thus, one component of 
a multicomponent product might be listed because of its toxicity, another 
component because of its flatranability, while a third component could be 
included both for its toxicity and its reactivity. Note that a MSDS for a 
single component product must have the name of the material repeated in 
this section to avoid giving the impression that there are no hazardous 
ingredients.
Chemical substances should be listed according to their complete name 
derived from a recognized system of nomenclature. Where possible, avoid 
using common names and general class names such as "aromatic amine," 
"safety solvent," or "aliphatic hydrocarbon" when the specific name is 
known.
The may be the approximate percentage by weight or volume
(indicate basis) which each hazardous ingredient of the mixture bears to 
the whole mixture. This may be indicated as a range or maximum amount, ie, 
"10-40% vol" or "10% max wt" to avoid disclosure of trade secrets.
Toxic hazard data shall be stated in terms of concentration, mode of 
exposure or test, and animal used, eg, "100 ppm LC50-rat," "25 mg/kg LD50- 
skin-rabbit," "75 ppm LC man," or "permissible exposure from 29 CFR 
1910.1000," or if not available, from other sources of publications such as 
the American Conference of Governmental Industrial Hygienists or the 
American National Standards Institute Inc. Flashpoint, shock sensitivity,
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or similar descriptive data may be used to indicate flammability, 
reactivity, or similar hazardous properties of the material.
(c) Section III. Physical Data
The data in Section III should be for the total mixture and should 
include the boiling point and melting point in degrees Fahrenheit (Celsius 
in parentheses); vapor pressure, in millimeters of mercury (mmHg); vapor 
density of gas or vapor (air = 1); solubility in water, in parts/hundred 
parts of water by weight; specific gravity (water = 1); percent volatiles 
(indicated if by weight or volume) at 70 degrees Fahrenheit (21.1 degrees 
Celsius); evaporation rate for liquids or sublimable solids, relative to 
butyl acetate; and appearance and odor. These data are useful for the 
control of toxic substances. Boiling point, vapor density, percent 
volatiles, vapor pressure, and evaporation are useful for designing proper 
ventilation equipment. This information is also useful for design and 
deployment of adequate fire and spill containment equipment. The 
appearance and odor may facilitate identification of substances stored in 
improperly marked containers, or when spilled.
(d) Section IV. Fire and Explosion Data
Section IV should contain complete fire and explosion data for the 
product, including flashpoint and autoignition temperature in degrees 
Fahrenheit (Celsius in parentheses); flammable limits, in percent by volume 
in air; suitable extinguishing media or materials; special firefighting 
procedures; and unusual fire and explosion hazard information. If the 
product presents no fire hazard, insert "NO FIRE HAZARD" on the line 
labeled "Extinguishing Media."
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(e) Section V. Health Hazard Information
The "Health Hazard Data" should be a combined estimate of the hazard 
of the total product. This can be expressed as a TWA concentration, as a 
permissible exposure, or by some other indication of an acceptable 
standard. Other data are acceptable, such as lowest LC50 if multiple 
components are involved.
Under "Routes of Exposure," comments in each category should reflect
the potential hazard from absorption by the route in question. Comments
should indicate the severity of the effect and the basis for the statement
if possible. The basis might be animal studies, analogy with similar 
products, or human experiences. Comments such as "yes" or "possible" are 
not helpful. Comments pertinent to acrylamide might be:
Skin Contact— single short contact, no adverse effects likely; 
prolonged or repeated contact, possibly mild irritation,
erythema, and skin peeling.
Eye Contact— some pain and mild transient irritation;
conjunctival injury.
"Emergency and First Aid Procedures" should be written in lay 
language and should primarily represent first-aid treatment that could be 
provided by paramedical personnel or individuals trained in first aid.
Information in the "Notes to Physician" section should include any 
special medical information which would be of assistance to an attending 
physician including required or recommended preplacement and periodic 
medical examinations, diagnostic procedures, and medical management of 
overexposed employees.
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(f) Section VI. Reactivity Data
The comments in Section VI relate to safe storage and handling of 
hazardous, unstable substances. It is particularly important to highlight 
instability or incompatibility to common substances or circumstances, such 
as water, direct sunlight, steel or copper piping, acids, alkalies, etc. 
"Hazardous Decomposition Products" shall include those products released 
under fire conditions. It must also include dangerous products produced by 
aging, such as peroxides in the case of some ethers. Where applicable, 
shelf life should also be indicated.
(g) Section VII. Spill or Leak Procedures
Detailed procedures for cleanup and disposal should be listed with 
emphasis on precautions to be taken to protect employees assigned to
cleanup detail. Specific neutralizing chemicals or procedures should be
described in detail. Disposal methods should be explicit including proper 
labeling of containers holding residues and ultimate disposal methods such 
as "sanitary landfill" or "incineration." Warnings such as "comply with
local, state, and federal antipollution ordinances" are proper but not 
sufficient. Specific procedures shall be identified.
(h) Section VIII. Special Protection Information
Section VIII requires specific information. Statements such as 
"Yes," "No," or "If necessary" are not informative. Ventilation 
requirements should be specific as to type and preferred methods. 
Respirators shall be specified as to type and NIOSH or US Bureau of Mines 
approval class, ie, "Supplied air," "Organic vapor canister," etc. 
Protective equipment must be specified as to type and materials of
construction.
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(i) Section IX. Special Precautions
"Precautionary Statements" shall consist of the label statements 
selected for use on the container or placard. Additional information on 
any aspect of safety or health not covered in other sections should be 
inserted in Section IX. The lower block can contain references to 
published guides or in-house procedures for handling and storage. 
Department of Transportation markings and classifications and other 
freight, handling, or storage requirements and environmental controls can 
be noted.
(j) Signature and Filing
Finally, the name and address of the responsible person who completed 
the MSDS and the date of completion are entered. This will facilitate 
correction of errors and identify a source of additional information.
The MSDS shall be filed in a location readily accessible to employees 
exposed to the hazardous substance. The MSDS can be used as a training aid 
and basis for discussion during safety meetings and training of new 
employees. It should assist management by directing attention to the need 
for specific control engineering, work practices, and protective measures 
to ensure safe handling and use of the material. It will aid the safety 
and health staff in planning a safe and healthful work environment and in 
suggesting appropriate emergency procedures and sources of help in the 
event of harmful exposure of employees.
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MATERIAL SAFETY DATA SHEET
1 PRODUCT IDENTIFICATION
M A N U F A C T U R E R ’S N A ME R E G U L A R  T E L E P H O N E  NO E M E R G E N C Y  T E L E P H O N E  NO
A D D R E S S
TRADE NAME
SYNONYMS
II HAZARDOUS INGREDIENTS
M A T E R I A L  O R  C O M P O N E N T % H A Z A R D  D A T A
III PHYSICAL DATA
B O I L I N G  P O I N T ,  7 6 0  MM HG M E L T I N G  PO I N T
S P E C I F I C  G R A V I T Y  | H 2 0  = 1) V A P O R  P R E S S U R E
V A P O R  D E N S I T Y  I AI R = 11 S O L U B I L I T Y  IN H 2 0 .  % BY WT
%  V O L A T I L E S  BY VO L E V A P O R A T I O N  R A T E  ( B U T Y L  A C E T A T E  ; 1}
A P P E A R A N C E  A N D  O D O R
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IV FIRE AND EXPLOSION DATA
f l a s h  p o i n t
( T E S T  M E T H O D )
A U T O I G N I T I O N
t e m p e r a t u r e
f l a m m a b l e  l i m i t s  i n  a i r , %  b y  v o l . L O WE R u p p e r
e x t i n g u i s h i n g
m e d i a
S P E C I A L  F I R E
F I G H T I N G
P R O C E D U R E S
U N U S U A L  FI RE 
A N D  E X P L O S I O N  
H A Z A R D
V HEALTH HAZARD INFORMATION
H E A L T H  H A Z A R D  D A T A
R O U T E S  O F  E X P O S U R E  
I N H A L A T I O N
S K I N C O N T A C T
S KI N A B S O R P T I O N
E YE C O N T A C T
I N G E S T I O N
E F F E C T S  OF  O V E R E X P O S U R E  
A C U T E  O V E R E X P O S U R E
C H R O N I C  O V E R E X P O S U R E
E M E R G E N C Y  A N D  F I R S T  A I D  P R O C E D U R E S  
E YES
S KI N
I N H A L A T I O N
I N G E S T I O N
N O T E S  T O P HYS I C I AN
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VI REACTIVITY DATA
C O N D I T I O N S  C O N T R I B U T I N G  T O  I N S T A B I L I T Y
I N C O MP A 1  i BI L I T Y
H A Z A R D O U S  D E C O M P O S I T I O N  P R O D U C T S
C O N D I T I O N S  C O N T R I B U T I N G  T O  H A Z A R D O U S  P O L Y M E R I Z A T I O N
VII SPILL OR LEAK PROCEDURES
S T E P S  T O  BE T A K E N  IF M A T E R I A L  IS R E L E A S E O  O R  S P I L L E D
N E U T R A L I Z I N G  C H E M I C A L S
WA S T E  D I S P O S A L  M E T H O D
VIII SPECIAL PROTECTION INFORMATION
V E N T I L A T I O N  R E Q U I R E M E N T S
S P E C I F I C  P E R S O N A L  P R O T E C T I V E  E Q U I P M E N T
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P R E C A U T I O N A R Y
S T A T E M E N T S
IX SPECIAL PRECAUTIONS
O T H E R  H A N D L I N G  A N D  
S T O R A G E  R E Q U I R E M E N T S
P R E P A R E D  BY
A D D R E S S
DATE
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XII. TABLES AND FIGURE
TABLE XII-1
PHYSICAL AND CHEMICAL PROPERTIES OF ACRYLAMIDE
Molecular formula CH2=CHC0NH2
Formula weight 71.08
Melting point 84.5 ± 0.3 C
Vapor pressure 0.007 mmHg at 25 C 
0.033 mmHg at 40 C 
0.07 mmHg at 50 C
Appearance White crystalline solid
Boiling point 87 C at 2 mmHg 
103 C at 5 mmHg 
125 C at 25 mmHg
Heat of polymerization 19.8 kcal/mole
Density 1.122 g/ml at 30 C
Solubility in g/100 ml of solvent at 30 C:
acetone 63.1
benzene 0.346
chloroform 2.66
ethanol 86.2
ethyl acetate 12.6
n-heptane 0.0068
methanol 155
water 215.5
Adapted from Kirk-Othmer Encyclopedia of Chemical Technology [1]
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TABLE XII-2
OCCUPATIONS WITH POTENTIAL EXPOSURE TO ACRYLAMIDE
Acrylamide manufacturing workers 
Adhesive tape-making workers 
Chemical grouting workers 
Electrophoretic gel-making workers 
Flocculator workers 
Papermaking workers 
Soil stabilization workers 
Surface coating workers 
Synthetic fiber-making workers 
Textile workers 
Well drillers
Adapted from Chemistry of Acrylamide [3]
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TABLE XI1-3
SAMPLING DATA FROM AN ACRYLAMIDE MANUFACTURING PLANT
Job Description Date Airborne Exposure to Acrylamide*
Personal Stationary
Monitoring Data Site Data
Supervisor, preparation and 4/29/75 0.5 0.2
mixing of solution 4/30/75 0.7 0.2
0 . 6 0 . 2
5/2/75 0.6 0.2
0.5 0.2
5/5/75 0.8 0.2
5/6/75 0.2 0.1
0 . 2 0 . 1
5/7/75 1.5 0.2
Bagging 1/6/75 0.5 0.1
1/7/75 3.6 0.1
1/10/75 0.5 0.2
1/14/75 0.6 0.1
1/15/75 0.7 0.1
1/16/75 2.0 0.1
1/17/75 1.3 0.2
2/7/75 0.3 0.1
2/10/75 0.3 0.1
2/11/75 2.3 0.3
2/12/75 0.5 0.1
2/14/75 0.3 0.2
4/29/75 1.8 0.2
5/28/75 0.8 0.2
General, solid only 9/5/74 0.5 0.1
5/8/75 0.7 0.2
5/12/75 0.4 0.2
5/13/75 0.3 0.1
5/15/75 0.5 0.2
5/16/75 1.8 0.2
General, solutions only 5/8/75 0.7 0.2
5/13/75 0.5 0.1
5/15/75 0.2 0.2
5/16/75 0.1 0.2
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TABLE XII-3 (CONTINUED)
SAMPLING DATA FROM AN ACRYLAMIDE MANUFACTURING PLANT
Job Description Date Airborne Exposure
Personal 
Monitoring Data
to Acrylamide*
Stationary 
Site Data
General, solutions and solid 5/7/75 0.4 0.2
5/9/75 0.6 0.3
I t 0.8 0.3
5/14/75 0.3 0.1
I t 1.0 0.1
*A11 concentrations are given in mg/cu m for 8-hr exposures.
Adapted from Brinkley (written communication, June 1976)
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Soap
Solution
Manometer
(water)
FIGURE X II—1 CALIBRATION SETUP FOR PERSONAL SAMPLING PUMP 
WITH MIDGET IMPINGER
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